nach oben

Journal of Interventional Cardiac Electrophysiology

Erschienen in:

Open Access 20.01.2020

2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary

verfasst von: Edmond M. Cronin, Frank M. Bogun, Philippe Maury, Petr Peichl, Minglong Chen, Narayanan Namboodiri, Luis Aguinaga, Luiz Roberto Leite, Sana M. Al-Khatib, Elad Anter, Antonio Berruezo, David J. Callans, Mina K. Chung, Phillip Cuculich, Andre d’Avila, Barbara J. Deal, Paolo Della Bella, Thomas Deneke, Timm-Michael Dickfeld, Claudio Hadid, Haris M. Haqqani, G. Neal Kay, Rakesh Latchamsetty, Francis Marchlinski, John M. Miller, Akihiko Nogami, Akash R. Patel, Rajeev Kumar Pathak, Luis C. Saenz Morales, Pasquale Santangeli, John L. Sapp Jr, Andrea Sarkozy, Kyoko Soejima, William G. Stevenson, Usha B. Tedrow, Wendy S. Tzou, Niraj Varma, Katja Zeppenfeld

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 1/2020

Abstract

Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past decade in our understanding of these arrhythmias and in our ability to diagnose and treat them. The field of catheter ablation has progressed with the development of new methods and tools, and with the publication of large clinical trials. Therefore, global cardiac electrophysiology professional societies undertook to outline recommendations and best practices for these procedures in a document that will update and replace the 2009 EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias. An expert writing group, after reviewing and discussing the literature, including a systematic review and meta-analysis published in conjunction with this document, and drawing on their own experience, drafted and voted on recommendations and summarized current knowledge and practice in the field. Each recommendation is presented in knowledge byte format and is accompanied by supportive text and references. Further sections provide a practical synopsis of the various techniques and of the specific ventricular arrhythmia sites and substrates encountered in the electrophysiology lab. The purpose of this document is to help electrophysiologists around the world to appropriately select patients for catheter ablation, to perform procedures in a safe and efficacious manner, and to provide follow-up and adjunctive care in order to obtain the best possible outcomes for patients with ventricular arrhythmias.

ESM 1 (PDF 2569 kb)

Electronic supplementary material

The online version of this article (https://doi.org/10.1007/s10840-019-00664-2) contains supplementary material, which is available to authorized users.

Published by Elsevier Inc./Oxford University Press/Wiley. This article is published under the Creative Commons CC-BY license.

Document Reviewers: Samuel J. Asirvatham, MD, FHRS; Eduardo Back Sternick, MD, PhD; Janice Chyou, MD; Sabine Ernst, MD, PhD; Guilherme Fenelon, MD, PhD; Edward P. Gerstenfeld, MD, MS, FACC; Gerhard Hindricks, MD; Koichi Inoue, MD, PhD; Jeffrey J. Kim, MD; Kousik Krishnan, MD, FHRS, FACC; Karl-Heinz Kuck, MD, FHRS; Martin Ortiz Avalos, MD; Thomas Paul, MD, FACC, FHRS; Mauricio I. Scanavacca, MD, PhD; Roderick Tung, MD, FHRS; Jamie Voss, MBChB; Takumi Yamada, MD; Teiichi Yamane, MD, PhD, FHRS

Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Developed in collaboration with and endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Japanese Heart Rhythm Society (JHRS), the Pediatric and Congenital Electrophysiology Society (PACES), and the Sociedade Brasileira de Arritmias Cardíacas (SOBRAC). Endorsed by the Canadian Heart Rhythm Society. For copies of this document, please contact the Elsevier Inc. Reprint Department (reprints@elsevier.com). Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the Heart Rhythm Society. Instructions for obtaining permission are located at https://www.elsevier.com/about/our-business/policies/copyright/permissions. This article has been copublished in Heart Rhythm, Europace, and the Journal of Arrhythmia. Correspondence: Heart Rhythm Society, 1325 G Street NW, Suite 400, Washington , DC 20005. E-mail address: clinicaldocs@hrsonline.org

Edmond M. Cronin is the Chair.

Frank M. Bogun is the Vice-Chair.

Philippe Maury is the Chair representing the European Heart Rhythm Association (EHRA).

Petr Peichl is the Vice-Chair representing the European Heart Rhythm Association (EHRA).

Minglong Chen is the Chair representing the Asia Pacific Heart Rhythm Society (APHRS).

Narayanan Namboodiri is the Vice-Chair representing the Asia Pacific Heart Rhythm Society (APHRS).

Luis Aguinaga is the Chair representing the Latin American Heart Rhythm Society (LAHRS).

Luiz Roberto Leite is the Vice-Chair representing the Latin American Heart Rhythm Society (LAHRS).

Antonio Berruezo, Paolo Della Bella, Thomas Deneke, Andrea Sarkozy and Katja Zeppenfeld are the Representatives of the European Heart Rhythm Association (EHRA).

Mina K. Chung and John M. Miller are the Representatives of the American College of Cardiology (ACC).

Andre d’Avila is the Representative of the Sociedade Brasileira de Arritmias Cardíacas (SOBRAC).

Barbara J. Deal is the Representative of the American Heart Association (AHA).

Claudio Hadid and Luis C. Saenz Morales are the Representatives of the Latin American Heart Rhythm Society (LAHRS).

Haris M. Haqqani, Rajeev Kumar Pathak and Kyoko Soejima are the Representatives of the Asia Pacific Heart Rhythm Society (APHRS).

Akihiko Nogami is the Representative of the Japanese Heart Rhythm Society (JHRS).

Akash R. Patel is the Representative of the Pediatric and Congenital Electrophysiology Society (PACES).

Sana M. Al-Khatib, Elad Anter, David J. Callans, Phillip Cuculich, Timm-Michael Dickfeld, G. Neal Kay, Rakesh Latchamsetty, Francis Marchlinski, Pasquale Santangeli, John L. Sapp Jr, William G. Stevenson, Usha B. Tedrow, Wendy S. Tzou and Niraj Varma are the Representatives of the Heart Rhythm Society (HRS).

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

AAD

Antiarrhythmic drug

AIV

Anterior interventricular vein

AMC

Aortomitral continuity

ARVC

Arrhythmogenic right ventricular cardiomyopathy

ATP

Antitachycardia pacing

Atrioventricular

BBRVT

Bundle branch reentrant ventricular tachycardia

CHD

Congenital heart disease

CMR

Cardiac magnetic resonance imaging

COR

Class of recommendation

Coronary sinus

DCM

Dilated cardiomyopathy

EAM

Electroanatomical mapping

ECG

Electrocardiogram

GCV

Great cardiac vein

HCM

Hypertrophic cardiomyopathy

Hemodynamic support

ICD

Implantable cardioverter defibrillator

ICE

Intracardiac echocardiography

ICM

Ischemic cardiomyopathy

IHD

Ischemic heart disease

LBB

Left bundle branch

LBBB

Left bundle branch block

LMNA

Lamin A/C

LOE

Level of evidence

LSV

Left sinus of Valsalva

Left ventricle

LVOT

Left ventricular outflow tract

NCSV

Noncoronary sinus of Valsalva

NICM

Nonischemic cardiomyopathy

PES

Programmed electrical stimulation

PVC

Premature ventricular complex

RBB

Right bundle branch

RBBB

Right bundle branch block

RSV

Right sinus of Valsalva

Right ventricle

RVOT

Right ventricular outflow tract

RWI

Relationship with industry and other entities

SHD

Structural heart disease

Sinus of Valsalva

Ventricular arrhythmia

Ventricular fibrillation

Ventricular tachycardia

TABLE OF CONTENTS

Section 1

Introduction .......................................in this issue

1.1.

Document Scope and Rationale ...........in this issue

1.2.

Methods .................................................in this issue

Section 2

Background ........................................in this issue

Section 3

Clinical Evaluation .............................in this issue

3.1.

Clinical Presentation .............................in this issue

3.2.

Diagnostic Evaluation ...........................in this issue

3.2.1.

Resting 12-Lead Electrocardiogram ...in this issue

3.2.2.

Assessment of Structural Heart Disease and Myocardial Ischemia ......................in this issue

3.2.3.

Risk Stratification in the Setting of Frequent Premature Ventricular Complexes ...in this issue

3.2.4.

Longitudinal Follow-up in the Setting of Frequent Premature Ventricular Complexes ...in this issue

Section 4

Indications for Catheter Ablation .......in this issue

4.1.

Idiopathic Outflow Tract Ventricular Arrhythmia ...

4.2.

Idiopathic Nonoutflow Tract Ventricular Arrhythmia ..........................................in this issue

4.3.

Premature Ventricular Complexes With or Without Left Ventricular Dysfunction ................in this issue

4.4.

Ventricular Arrhythmia in Ischemic Heart Disease ...in this issue

4.5.

Nonischemic Cardiomyopathy .............in this issue

4.6.

Ventricular Arrhythmia Involving the His-Purkinje System, Bundle Branch Reentrant Ventricular Tachycardia, and Fascicular Ventricular Tachycardia ...........................................in this issue

4.7.

Congenital Heart Disease .....................in this issue

4.8.

Inherited Arrhythmia Syndromes ..........in this issue

4.9.

Ventricular Arrhythmia in Hypertrophic Cardiomyopathy ..................................in this issue

Section 5

Procedural Planning ...in this issue

Section 6

Intraprocedural Patient Care ..............in this issue

6.1.

Anesthesia .............................................in this issue

6.2.

Vascular Access .....................................in this issue

6.3.

Epicardial Access ..................................in this issue

6.4.

Intraprocedural Hemodynamic Support ...in this issue

6.5.

Intraprocedural Anticoagulation ...........in this issue

Section 7

Electrophysiological Testing ..............in this issue

Section 8

Mapping and Imaging Techniques ....in this issue

8.1.

Overview ...............................................in this issue

8.2.

Substrate Mapping in Sinus Rhythm ...in this issue

8.3.

Intraprocedural Imaging During Catheter Ablation of Ventricular Arrhythmias ....................in this issue

8.4.

Electroanatomical Mapping Systems and Robotic Navigation ...in this issue

Section 9

Mapping and Ablation .......................in this issue

9.1.

Ablation Power Sources and Techniques ..in this issue.

9.2.

Idiopathic Outflow Tract Ventricular Arrhythmia ...in this issue

9.3.

Idiopathic Nonoutflow Tract Ventricular Arrhythmia ...in this issue

9.4.

Bundle Branch Reentrant Ventricular Tachycardia and Fascicular Ventricular Tachycardia ...in this issue

9.5.

Postinfarction Ventricular Tachycardia ...in this issue

9.6.

Dilated Cardiomyopathy ......................in this issue

9.7.

Ventricular Tachycardia Ablation in Hypertrophic Cardiomyopathy ...................................in this issue

9.8.

Brugada Syndrome ...............................in this issue

9.9.

Polymorphic Ventricular Tachycardia/Ventricular Fibrillation Triggers ..............................in this issue

9.10.

Arrhythmogenic Right Ventricular Cardiomyopathy ..............................in this issue

9.11.

Mapping and Ablation in Congenital Heart Disease ...............................................in this issue

9.12.

Sarcoidosis ..........................................in this issue

9.13.

Chagas Disease ...................................in this issue

9.14.

Miscellaneous Diseases and Clinical ScenariosWith Ventricular Tachycardia ...in this issue

9.15.

Surgical Therapy ...in this issue

9.16.

Sympathetic Modulation ....................in this issue

9.17.

Endpoints of Catheter Ablation of Ventricular Tachycardia ........................................in this issue

Section 10

Postprocedural Care .........................in this issue

10.1.

Postprocedural Care: Access, Anticoagulation, Disposition .........................................in this issue

10.1.1.

Postprocedural Care: Access ...in this issue

10.1.2.

Postprocedural Care:Anticoagulation ...in this issue

10.2.

Incidence and Management of Complications ...in this issue

10.3.

Hemodynamic Deterioration and Proarrhythmia ...in this issue

10.4.

Follow-up of Patients Post Catheter Ablation of Ventricular Tachycardia ......................in this issue

Section 11

Training and Institutional Requirements and Competencies ..................................in this issue

11.1.

Training Requirements and Competencies for Catheter Ablation of Ventricular Arrhythmias ...in this issue

11.2.

Institutional Requirements for Catheter Ablation of Ventricular Tachycardia ..................in this issue

Section 12

Future Directions .............................in this issue

Appendix 1

Author Disclosure Table ................in this issue

Appendix 2

Reviewer Disclosure Table ............in this issue

1 Introduction

1.1 Document Scope and Rationale

The field of electrophysiology has undergone rapid progress in the last decade, with advances both in our understanding of the genesis of ventricular arrhythmias (VAs) and in the technology used to treat them. In 2009, a joint task force of the European Heart Rhythm Association (EHRA) and the Heart Rhythm Society (HRS), in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA), produced an expert consensus document that outlined the state of the field and defined the indications, techniques, and outcome measures of VA ablation [1]. In light of advances in the treatment of VAs in the interim, and the growth in the number of VA ablations performed in many countries and regions [2, 3], an updated document is needed. This effort represents a worldwide partnership between transnational cardiac electrophysiology societies, namely, HRS, EHRA, the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS), and collaboration with ACC, AHA, the Japanese Heart Rhythm Society (JHRS), the Brazilian Society of Cardiac Arrhythmias (Sociedade Brasileira de Arritmias Cardíacas [SOBRAC]), and the Pediatric and Congenital Electrophysiology Society (PACES). The consensus statement was also endorsed by the Canadian Heart Rhythm Society (CHRS).

This clinical document is intended to supplement, not replace, the 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death [4] and the 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death [5]. The scope of the current document relates to ablation therapy for VAs, from premature ventricular complexes (PVCs) to monomorphic and polymorphic ventricular tachycardia (VT) and triggers of ventricular fibrillation (VF). Due to its narrower scope, the consensus statement delves into greater detail with regard to indications and technical aspects of VA ablation than the above-mentioned guidelines.

Where possible, the recommendations in this document are evidence based. It is intended to set reasonable standards that can be applicable worldwide, while recognizing the different resources, technological availability, disease prevalence, and health care delivery logistics in various parts of the world. In addition, parts of this document, particularly Section 9, present a practical guide on how to accomplish the procedures described in a manner that reflects the current standard of care, while recognizing that some procedures are better performed, and some disease states better managed, in settings in which there is specific expertise.

1.2 Methods

The writing group was selected according to each society’s procedures, including content and methodology experts representing the following organizations: HRS, EHRA, APHRS, LAHRS, ACC, AHA, JHRS, PACES, and SOBRAC. Each partner society nominated a chair and co-chair, who did not have relevant relationships with industry and other entities (RWIs). In accordance with HRS policies, disclosure of any RWIs was required from the writing committee members (Appendix 1) and from all peer reviewers (Appendix 2). Of the 38 committee members, 17 (45%) had no relevant RWIs. Recommendations were drafted by the members who did not have relevant RWIs. Members of the writing group conducted comprehensive literature searches of electronic databases, including Medline (via PubMed), Embase, and the Cochrane Library. Evidence tables were constructed to summarize the retrieved studies, with nonrandomized observational designs representing the predominant form of evidence (Supplementary Appendix 3). Case reports were not used to support recommendations. Supportive text was drafted in the “knowledge byte” format for each recommendation. The writing committee discussed all recommendations and the evidence that informed them before voting. Initial failure to reach consensus was resolved by subsequent discussions, revisions as needed, and re-voting. Although the consensus threshold was set at 67%, all recommendations were approved by at least 80% of the writing committee members. The mean consensus over all recommendations was 95%. A quorum of two-thirds of the writing committee was met for all votes [6].

Each recommendation in this document was assigned a Class of Recommendation (COR) and a Level of Evidence (LOE) according to the system developed by ACC and AHA (Table 1) [7]. The COR denotes the strength of the recommendation based on a careful assessment of the estimated benefits and risks; COR I indicates that the benefit of an intervention far exceeds its risk; COR IIa indicates that the benefit of the intervention moderately exceeds the risk; COR IIb indicates that the benefit may not exceed the risk; and COR III indicates that the benefit is equivalent to or is exceeded by the risk. The LOE reflects the quality of the evidence that supports the recommendation. LOE A is derived from high-quality randomized controlled trials; LOE B-R is derived from moderate-quality randomized controlled trials; LOE B-NR is derived from well-designed nonrandomized studies; LOE C-LD is derived from randomized or nonrandomized studies with limitations of design or execution; and LOE C-EO indicates that a recommendation was based on expert opinion [7].

Table 1

ACC/AHA Recommendation System: Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, and Diagnostic Testing in Patient Care^*

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tab1_HTML.png

Reproduced with permission of the American College of Cardiology (ACC) and the American Heart Association (AHA) [7]

Unique to this consensus statement is the systematic review commissioned specifically for this document as part of HRS’s efforts to adopt the rigorous methodology required for guideline development. The systematic review was performed by an experienced evidence-based practice committee based at the University of Connecticut, which examined the question of VT ablation vs control in patients with VT and ischemic heart disease (IHD) [8]. The question, in PICOT format, was as follows: In adults with history of sustained VT and IHD, what is the effectiveness and what are the detriments of catheter ablation compared with other interventions? Components of the PICOT were as follows: P = adults with history of sustained VT and IHD; I = catheter ablation; C = control (no therapy or antiarrhythmic drug [AAD]); O = outcomes of interest, which included 1) appropriate implantable cardioverter defibrillator (ICD) therapies (ICD shock or antitachycardia pacing [ATP]), 2) appropriate ICD shocks, 3) VT storm (defined as three shocks within 24 hours), 4) recurrent VT/VF, 5) cardiac hospitalizations, and 6) all-cause mortality; and T = no time restrictions.

An industry forum was conducted to achieve a structured dialogue to address technical questions and to gain a better understanding of future directions and challenges. Because of the potential for actual or perceived bias, HRS imposes strict parameters on information sharing to ensure that industry participates only in an advisory capacity and has no role in either the writing of the document or its review.

The draft document underwent review by the HRS Scientific and Clinical Documents Committee and was approved by the writing committee. Recommendations were subject to a period of public comment, and the entire document underwent rigorous peer review by each of the participating societies and revision by the Chairs, before endorsement.

2 Background

This section reviews the history of VT ablation, details the mechanisms of VT, and provides definitions of frequently used terms (Table 2), including anatomic definitions (Table 3), as well as illustrating some types of sustained VA (Fig. 1).

Table 2

Definitions

Clinical Characteristics
Clinical ventricular tachycardia (VT): VT that has occurred spontaneously based on analysis of 12-lead electrocardiogram (ECG) QRS morphology.
Hemodynamically unstable VT: causes hemodynamic compromise requiring prompt termination.
Idiopathic VT: used to indicate VT that is known to occur in the absence of clinically apparent structural heart disease (SHD).
Idioventricular rhythm: three or more consecutive beats at a rate of up to 100 per minute that originate from the ventricles independent of atrial or atrioventricular (AV) nodal conduction. Although various arbitrary rates have been used to distinguish it from VT, the mechanism of ventricular rhythm is more important than the rate. Idioventricular rhythm can be qualified as “accelerated” when the rate exceeds 40 bpm.
Incessant VT: continuous sustained VT that recurs promptly despite repeated intervention for termination over several hours.
Nonclinical VT: VT induced by programmed electrical stimulation (PES) that has not been documented previously.
Nonsustained VT: terminates spontaneously within 30 seconds.
PVC: premature ventricular complex; it is an early ventricular depolarization with or without mechanical contraction. We recommend avoiding the use of the terms “ventricular premature depolarization” and “premature ventricular contraction” to standardize the literature and acknowledge that early electrical activity does not necessarily lead to mechanical contraction.
Presumptive clinical VT: similar to a spontaneous VT based on rate, limited ECG, or electrogram data available from ICD interrogation, but without the 12-lead ECG documentation of spontaneous VT.
PVC burden: the amount of ventricular extrasystoles, preferably reported as the % of beats of ventricular origin of the total amount of beats over a 24-hour recording period.
Repetitive monomorphic VT: continuously repeating episodes of self-terminating nonsustained VT.
Sustained VT: continuous VT for 30 seconds, or which requires an intervention for termination (such as cardioversion).
VT: a tachycardia (rate >100 bpm) with 3 or more consecutive beats that originates from the ventricles independent of atrial or AV nodal conduction.
VT storm: three or more separate episodes of sustained VT within 24 hours, each requiring termination by an intervention.
VT Morphologies
Monomorphic VT: a similar QRS configuration from beat to beat (Fig. 1a). Some variability in QRS morphology at initiation is not uncommon, followed by stabilization of the QRS morphology.
Monomorphic VT with indeterminate QRS morphology: preferred over ventricular flutter; it is a term that has been applied to rapid VT that has a sinusoidal QRS configuration that prevents identification of the QRS morphology.
Multiple monomorphic VTs: more than one morphologically distinct monomorphic VT, occurring as different episodes or induced at different times.
Pleomorphic VT: has more than one morphologically distinct QRS complex occurring during the same episode of VT, but the QRS is not continuously changing (Fig. 1b).
Polymorphic VT: has a continuously changing QRS configuration from beat to beat, indicating a changing ventricular activation sequence (Fig. 1c).
Right bundle branch block (RBBB)- and left bundle branch block (LBBB)-like VT configurations: terms used to describe the dominant deflection in V1, with a dominant R wave described as “RBBB-like” and a dominant S wave with a negative final component in V1 described as “LBBB-like” configurations.
Torsades de pointes: a form of polymorphic VT with continually varying QRS complexes that appear to spiral around the baseline of the ECG lead in a sinusoidal pattern. It is associated with QT prolongation.
Unmappable VT: does not allow interrogation of multiple sites to define the activation sequence or perform entrainment mapping; this could be due to hemodynamic intolerance that necessitates immediate VT termination, spontaneous or pacing-induced transition to other morphologies of VT, or repeated termination during mapping.
Ventricular fibrillation (VF): a chaotic rhythm defined on the surface ECG by undulations that are irregular in both timing and morphology, without discrete QRS complexes.
PVC Morphologies
Monomorphic PVC: PVCs felt reasonably to arise from the same focus. Slight changes in QRS morphology due to different exit sites from the same focus can be present.
Multiple morphologies of PVC: PVCs originating from several different focal locations.
Predominant PVC morphology: the one or more monomorphic PVC morphologies occurring most frequently and serving as the target for ablation.
Mechanisms
Focal VT: a point source of earliest ventricular activation with a spread of activation away in all directions from that site. The mechanism can be automaticity, triggered activity, or microreentry.
Scar-related reentry: arrhythmias that have characteristics of reentry that originate from an area of myocardial scar identified from electrogram characteristics or myocardial imaging. Large reentry circuits that can be defined over several centimeters are commonly referred to as “macroreentry.”

AV atrioventricular, ECG electrocardiogram, ICD implantable cardioverter defibrillator, LBBB left bundle branch block, PES programmed electrical stimulation, PVC premature ventricular complex, RBBB right bundle branch block, SHD structural heart disease, VT ventricular tachycardia

Table 3

Anatomical terminology

Term	Definition
RV inflow	The part of the right ventricle (RV) containing the tricuspid valve, chordae, and proximal RV.
RV outflow tract (RVOT)	The conus or infundibulum of the RV, derived from the bulbus cordis. It is bounded by the supraventricular crest and the pulmonic valve.
Tricuspid annulus	Area immediately adjacent to the tricuspid valve, including septal, free wall, and para-Hisian regions.
Moderator band	A muscular band in the RV, typically located in the mid to apical RV, connecting the interventricular septum to the RV free wall, supporting the anterior papillary muscle. It typically contains a subdivision of the right bundle branch (RBB).
RV papillary muscles	Three muscles connecting the RV myocardium to the tricuspid valve via the tricuspid chordae tendineae, usually designated as septal, posterior, and anterior papillary muscles. The septal papillary muscle is closely associated with parts of the RBB.
Supraventricular crest	Muscular ridge in the RV between the tricuspid and pulmonic valves, representing the boundary between the conus arteriosus and the rest of the RV. The exact components and terminology are controversial; however, some characterize it as being composed of a parietal band that extends from the anterior RV free wall to meet the septal band, which extends from the septal papillary muscle to meet it.
Pulmonary valves	The pulmonic valve includes three cusps and associated sinus, variously named right, left, and anterior; or anterolateral right, anterolateral left, and posterior sinuses. The posterior-right anterolateral commissure adjoins the aorta (junction of the right and left aortic sinuses). Muscle is present in each of the sinuses, and VA can originate from muscle fibers located within or extending beyond the pulmonary valve apparatus.
Sinuses of Valsalva (SV), aortic cusps, aortic commissures	The right (R), left (L), and noncoronary aortic valve cusps are attached to the respective SV. The left sinus of Valsalva (LSV) is posterior and leftward on the aortic root. The noncoronary sinus of Valsalva (NCSV) is typically the most inferior and posterior SV, located posterior and rightward, superior to the His bundle, and anterior and superior to the paraseptal region of the atria near the superior AV junctions, typically adjacent to atrial myocardium. The right sinus of Valsalva (RSV) is the most anterior cusp and may be posterior to the RVOT infundibulum. VAs can also arise from muscle fibers at the commissures (connections) of the cusps, or from myocardium accessible to mapping and ablation from this location, especially from the RSV/LSV junction.
LV outflow tract (LVOT)	The aortic vestibule, composed of an infra-valvular part, bounded by the anterior mitral valve leaflet, but otherwise not clearly distinguishable from the rest of the LV; the aortic valve; and a supra-valvular part.
LV ostium	The opening at the base of the LV to which the mitral and aortic valves attach.
Aortomitral continuity (AMC); aortomitral curtain, or mitral-aortic intervalvular fibrosa	Continuation of the anteromedial aspect of the mitral annulus to the aortic valve; a curtain of fibrous tissue extending from the anterior mitral valve leaflet to the left and noncoronary aortic cusps. The AMC is connected by the left and right fibrous trigones to ventricular myocardium, the right fibrous trigone to the membranous ventricular septum.
Mitral valve annulus	Area immediately adjacent to the mitral valve. This can be approached endocardially, or epicardially, either through the coronary venous system or percutaneously.
LV papillary muscles	Muscles connecting the mitral valve chordae tendineae to the LV, typically with posteromedial and anterolateral papillary muscles. Papillary muscle anatomy is variable and can have single or multiple heads.
LV false tendon (or LV moderator band)	A fibrous or fibromuscular chord-like band that crosses the LV cavity, attaching to the septum, papillary muscles, trabeculations, or free wall of the LV. They may contain conduction tissue and may impede catheter manipulation in the LV.
Posterior-superior process	The posterior-superior process of the left ventricle (LV) is the most inferior and posterior aspect of the basal LV, posterior to the plane of the tricuspid valve. VAs originating from the posterior-superior process of the LV can be accessed from the right atrium, the LV endocardium, and the coronary venous system.
Endocardium	Inner lining of the heart.
Purkinje network	The specialized conduction system of the ventricles, which includes the His bundle, RBB and left bundle branches (LBB), and the ramifications of these, found in the subendocardium. The Purkinje system can generate focal or reentrant VTs, typically manifesting Purkinje potentials preceding QRS onset.
Interventricular septum	Muscular wall between the LV and RV.
Membranous ventricular septum	The ventricular septum beneath the RSV and NCSV, through which the penetrating His bundle reaches the ventricular myocardium.
LV summit	Triangular region of the most superior part of the LV epicardial surface bounded by the left circumflex coronary artery, the left anterior descending artery, and an approximate line from the first septal coronary artery laterally to the left AV groove. The great cardiac vein (GCV) bisects the triangle. An area superior to the GCV is considered to be inaccessible to catheter ablation due to proximity of the coronary arteries and overlying epicardial fat.
Crux of the heart (crux cordis)	Epicardial area formed by the junction of the AV groove and posterior interventricular groove, at the base of the heart, approximately at the junction of the middle cardiac vein and coronary sinus (CS) and near the origin of the posterior descending coronary artery.
Epicardium	The outer layer of the heart—the visceral layer of the serous pericardium.
Epicardial fat	Adipose tissue variably present over the epicardial surface around coronary arteries, LV apex, RV free wall, left atrial appendage, right atrial appendage, and AV and interventricular grooves.
Pericardial space or cavity	The potential space between the parietal and visceral layers of serous pericardium, which normally contains a small amount of serous fluid. This space can be accessed for epicardial procedures.
Parietal pericardium	The layer of the serous pericardium that is attached to the inner surface of the fibrous pericardium and is normally apposed to the visceral pericardium, separated by a thin layer of pericardial fluid.
Fibrous pericardium	Thick membrane that forms the outer layer of the pericardium.
Subxiphoid area	Area inferior to the xiphoid process; typical site for percutaneous epicardial access.
Phrenic nerve	The right phrenic nerve lays along the right atrium and does not usually pass over ventricular tissue. The course of the left phrenic nerve on the fibrous pericardium can be quite variable and may run along the lateral margin of the LV near the left obtuse marginal artery and vein; inferior, at the base of the heart; or anterior over the sternocostal surface over the L main stem coronary artery or left anterior descending artery.
Coronary sinus (CS) and branches	The CS and its branches comprise the coronary venous system with the ostium of the CS opening into the right atrium. Tributaries of the CS, which runs along the left AV groove, may be used for mapping. These include the anterior interventricular vein (AIV), which arises at the apex and runs along the anterior interventricular septum, connecting to the GCV that continues in the AV groove to the CS; the communicating vein located between aortic and pulmonary annulus; various posterior and lateral marginal branches or perforator veins; and the middle cardiac vein that typically runs along the posterior interventricular septum from the apex to join the CS or empty separately into the right atrium. The junction of the GCV and the CS is at the vein or ligament of Marshall (or persistent left superior vena cava, when present), and the valve of Vieussens (where present).

Anatomical terminology [9‐17]. See also Figs. 3, 4, 7, and 8

AIV anterior interventricular vein, AMC aortomitral continuity, AV atrioventricular, CS coronary sinus, GCV great cardiac vein, LBB left bundle branch, LSV left sinus of Valsalva, LV left ventricle, LVOT left ventricular outflow tract, NCSV noncoronary sinus of Valsalva, RBB right bundle branch, RSV right sinus of Valsalva, RV right ventricle, RVOT right ventricular outflow tract, SV sinus of Valsalva, VA ventricular arrhythmia, VT ventricular tachycardia

3 Clinical Evaluation

This section discusses clinical presentations of patients with VAs and their workup as it pertains to documentation of arrhythmias and appropriate testing to assess for the presence of SHD.

3.1 Clinical Presentation

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Taba_HTML.png

3.2 Diagnostic Evaluation

3.2.1 Resting 12-Lead Electrocardiogram

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabb_HTML.png

3.2.2 Assessment of Structural Heart Disease and Myocardial Ischemia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabc_HTML.png

3.2.3 Risk Stratification in the Setting of Frequent Premature Ventricular Complexes

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabd_HTML.png

3.2.4 Longitudinal Follow-up in the Setting of Frequent Premature Ventricular Complexes

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabe_HTML.png

4 Indications for Catheter Ablation

Following are the consensus recommendations for catheter ablation of VAs organized by underlying diagnosis and substrate. These recommendations are each assigned a COR and an LOE according to the current recommendation classification system [47]. In drafting each of these recommendations, the writing committee took into account the published literature in the specific area, including the methodological quality and size of each study, as well as the collective clinical experience of the writing group when published data were not available. Implicit in each recommendation are several points: 1) the procedure is being performed by an electrophysiologist with appropriate training and experience in the procedure and in a facility with appropriate resources; 2) patient and procedural complexity vary widely, and some patients or situations merit a more experienced operator or a center with more capabilities than others, even within the same recommendation (eg, when an epicardial procedure is indicated and the operator or institution has limited experience with this procedure, it might be preferable to refer the patient to an operator or institution with adequate experience in performing epicardial procedures); 3) the patient is an appropriate candidate for the procedure, as outlined in Section 5, recognizing that the level of patient suitability for a procedure will vary widely with the clinical scenario; and 4) the patient’s (or designee’s) informed consent, values, and overall clinical trajectory are fundamental to a decision to proceed (or not) with any procedure. Therefore, in some clinical scenarios, initiation or continuation of medical therapy instead of an ablation procedure may be the most appropriate option, even when a class 1 recommendation for ablation is present. There may also be scenarios not explicitly covered in this document, and on which little or no published literature is available, in which the physician and patient must rely solely on their own judgment.

Figure 2 provides an overview of care for the patient with congenital heart disease (CHD) and VA.

4.1 Idiopathic Outflow Tract Ventricular Arrhythmia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabf_HTML.png

4.2 Idiopathic Nonoutflow Tract Ventricular Arrhythmia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabg_HTML.png

4.3 Premature Ventricular Complexes With or Without Left Ventricular Dysfunction

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabh_HTML.png

4.4 Ventricular Arrhythmia in Ischemic Heart Disease

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabi_HTML.png

4.5 Nonischemic Cardiomyopathy

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabj_HTML.png

4.6 Ventricular Arrhythmia Involving the His-Purkinje System, Bundle Branch Reentrant Ventricular Tachycardia, and Fascicular Ventricular Tachycardia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabk_HTML.png

4.7 Congenital Heart Disease

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabl_HTML.png

4.8 Inherited Arrhythmia Syndromes

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabm_HTML.png

4.9 Ventricular Arrhythmia in Hypertrophic Cardiomyopathy

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabn_HTML.png

5 Procedural Planning

This section includes preprocedural risk assessment (Table 4), preprocedural patient preparation, and preprocedural arrhythmia documentation with a focus on the regionalizing information of the ECG regarding the origin of VAs (Figs. 3 and 4). Furthermore, the capabilities of multimodality imaging in localizing the arrhythmogenic substrate are discussed in detail. Topics including the required equipment, personnel, and facility are detailed in this section.

Table 4

The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation

Variable	Points
Pulmonary disease (COPD)	5
Age >60	3
General anesthesia	4
Ischemic cardiomyopathy	6
NYHA class III/IV	6
EF <25%	3
VT storm	5
Diabetes mellitus	3

The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation, has values that range from 0 to 35 points (or 0 to 31 [PAINESD] when the modifiable intraprocedural variable “general anesthesia” is excluded) (Santangeli et al. Circ Arrhythm Electrophysiol 2015;8:68–75)

COPD chronic obstructive pulmonary disease, EF ejection fraction, NYHA New York Heart Association, VT ventricular tachycardia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabo_HTML.png

6 Intraprocedural Patient Care

Important aspects regarding intraprocedural sedation and its potential problems are highlighted in this section. Furthermore, vascular access, epicardial access with its many potential complications are discussed in detail, as well as anticoagulation and the indications for the use of hemodynamic support (HS) during VT ablation procedures.

6.1 Anesthesia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabp_HTML.png

6.2 Vascular Access

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabq_HTML.png

6.3 Epicardial Access

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabr_HTML.png

6.4 Intraprocedural Hemodynamic Support

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabs_HTML.png

6.5 Intraprocedural Anticoagulation

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabt_HTML.png

7 Electrophysiological Testing

The benefits and limitations of PES are detailed in this section.

8 Mapping and Imaging Techniques

8.1 Overview

Activation mapping with multipolar catheters, entrainment mapping (Figs. 5 and 6), and pace mapping are the main techniques used to map VAs. This section reviews these techniques including the technique of substrate mapping aiming to identify the arrhythmogenic substrate in sinus rhythm. Furthermore, intraprocedural imaging as it pertains to procedural safety and to identification of the arrhythmogenic substrate is reviewed in this section.

8.2 Substrate Mapping in Sinus Rhythm

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabu_HTML.png

8.3 Intraprocedural Imaging During Catheter Ablation of Ventricular Arrhythmias

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabv_HTML.png

8.4 Electroanatomical Mapping Systems and Robotic Navigation

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabw_HTML.png

9 Mapping and Ablation

This section is designed as a “how-to” section that details the procedural steps of VT ablation in different patient populations ranging from ablation of PVCs in patients without heart disease to ablation of VT/VF in patients with different types of SHD (Figs. 7, 8, 9, 10, 11 and 12 and Tables 5, 6, 7 and 8). Bullet points summarize the key points in this section.

Table 5

Types of bundle branch reentrant tachycardia

	Type A	Type B (Interfascicular tachycardia)	Type C
ECG morphology	LBBB pattern	RBBB pattern	RBBB pattern
Anterograde limb	RBB	LAF or LPF	LBB
Retrograde limb	LBB	LPF or LAF	RBB

LAF left anterior fascicle, LBB left bundle branch, LBBB left bundle branch block, LPF left posterior fascicle, RBB right bundle branch, RBBB right bundle branch block

Table 6

Fascicular ventricular tachycardias

I. Verapamil-sensitive fascicular reentrant VT
1. Left posterior type
i. Left posterior septal fascicular reentrant VT
ii. Left posterior papillary muscle fascicular reentrant VT
2. Left anterior type
i. Left anterior septal fascicular reentrant VT
ii. Left anterior papillary muscle fascicular reentrant VT
3. Upper septal type
II. Nonreentrant fascicular VT

VT ventricular tachycardia.

Table 7

Select recent radiofrequency catheter ablation studies in patients post myocardial infarction with a focus on substrate-based ablation strategies

Study	N	EF (%)	Prior CABG (%)	Inclusion	Access mapping catheter	Mapping strategy	Ablation strategy	Procedural endpoint	RF time procedural duration complications	VT recurrence and burden (follow-up)
Jais et al. (2012) [339] Two centers observational	70	35 ± 10	NR	1) Sustained VT resistant to AAD therapy and requiring external cardioversion or ICD therapies 2) SHD with ischemic or nonischemic dilated cardiomyopathy Exclusions: 1) VA attributable to an acute or reversible cause 2) Repetitive PVCs or nonsustained VT without sustained VT	Retrograde in 61 pts (87%) Transseptal in 32 pts (46%); epicardial access in 21 pts (31%) Dual access encouraged 3.5-mm external irrigated ablation catheter; multielectrode mapping catheter in 50% endocardial procedures and in all epicardial procedures	1) PES and activation mapping of induced stable VTs 2) Substrate mapping for LAVAs — sharp high-frequency electrograms often of low amplitude, occurring during or after the far-field ventricular electrogram, sometimes fractionated or multicomponent, poorly coupled to the rest of the myocardium	1) Ablation of LAVA in SR 2) Ablation of tolerated VTs guided by entrainment and activation mapping 3) Remapping (in stable patients) with further ablation if residual LAVA or persistent inducibility	1) Complete LAVA elimination — achieved in 47 of 67 pts with LAVA (70.1%) 2) Noninducibility — achieved in 70%, similar if LAVA eliminated or not	RF time 23 ± 11 min Procedure time 148 ± 73 min Complications 6 pts (8.6%): tamponade or bleeding managed conservatively (3), RV perforation requiring surgical repair (1); 3 pts died within 24 h due to low-flow state (2) plus arrhythmia recurrence (1), PEA (1)	Combined endpoint of VT recurrence or death occurred in 39 pts (55.7%); 45% of pts with LAVA elimination and 80% of those without VT recurrence in 32 (46%); 32% of pts with LAVA elimination and 75% of those without 7 cardiac deaths (10%) over 22 months of median follow-up
Di Biase et al. (2015) [302] VISTA trial Multicenter RCT	118	Group 1 33 ± 14 Group 2 32 ± 10	34%	1) Post-MI 2) Recurrent stable AAD refractory VT (symptomatic or requiring ICD therapy) Exclusion: syncope, cardiac arrest, prior failed ablation, renal failure,end-stage heart failure	Endocardial Epicardial when clinical VTs were inducible after endocardial ablation + no CABG Group 1: 11.7% Group 2: 10.3% 3.5-mm tip	1) Substrate mapping (BV ≤1.5 mV) + Group 1 2) PES and activation mapping/pace mapping for clinical and stable nonclinical VT (unstable VT not targeted)	Group 1: Clinical VT ablation, linear lesion to transect VT isthmus Group 2: Extensive substrate ablation targeting any abnormal potential (=fractionated and/or LP)	Group 1: Noninducibility of clinical VT — achieved in 100% Group 2: 1) Elimination of abnormal potentials 2) No capture from within the scar (20 mA) 3) Noninducibility of clinical VT — achieved in 100%	Group 1: RF time 35 ± 27 min Procedural time 4.6 ± 1.6 h Group 2: RF time 68 ± 27 min (P < .001) Procedural time 24.2 ± 1.3 h (P = .13) Complications 5%	VT recurrence at 12 months Group 1: 48.3% Group 2: 15.5% P < .001 Mortality at 12 months Group 1: 15% Group 2: 8.6% P = .21
Tilz et al. (2014) [340] Single center observational	12 12/117 pts with post-MI VT	32 ± 13	—	1) Presence of a circumscribed dense scar (BV <1.5 mV, area <100 cm²) 2) Recurrent unmappable VT 3) Post-MI Exclusion: patchy scar/multiple scars	Endocardial 3.5-mm tip	1) PES 2) Substrate mapping: area of BV <1.5 mV + double, fractionated or LP 3) PES after ablation	Circumferential linear lesion along BZ (BV <1.5 mV) to isolate substrate	1) Lack of abnormal EGMs within area 2) No capture within area — achieved in 50% 3) Max. 40 RF lesion Noninducibility of any VT (no predefined endpoint) —observed in 92%	RF time 53 ± 15 min Procedure time 195 ± 64 min No complication	VT recurrence 33% Median follow-up 497 days
Tzou et al. (2015) [341] Two centers observational	44 Post-MI 32 44/566 pts with SHD	31 ± 13	—	1) SHD 2) AAD refractory VT 3) Intention to achieve core isolation	Endocardial Epicardial post-MI 6% 3.5-mm tip Selected patients: multi-electrode catheters for exit block evaluation	1) BV mapping 2) PES 3) Activation mapping 4) Substrate mapping Dense scar BV <0.5 mV; BZ BV 0.5–1.5 mV/voltage channels/ fractionated/LP; pace-match, S-QRS >40 ms 5) PES after core isolation	1) Circumferential linear lesion to isolate core (=confluent area of BV <0.5 mV area and regions with BV <1 mV harbouring VT-related sites 2) Targeting fractionated and LP within core 3) Targeting VT-related sites outside core (2 and 3 in 59%)	1) No capture of the ventricle during pacing inside core 2) Dissociation of isolated potentials — core isolation achieved in 70% post-MI 3) Noninducibility —achieved in 84%	RF lesions 111 ± 91 Procedure time 326 ± 121 min Complications 2.2% No death	VT recurrence 14% Follow-up 17.5 ± 9 months
Silberbauer et al. (2014) [342] One center observational	160	28 ± 9.5 inducible after RFCA 34 ± 9.2 endpoint reached	22.5%	1) Post-MI 2) AAD refractory VT 3) First VT ablation at the center	Endocardial Combined endoepicardial (20%) — Clinical findings — Prior ablation — Research protocol 3.5-mm tip/4-mm tip	1) Substrate mapping: BV <1.5 mV + LP (=continuous, fragmented bridging to components after QRS offset/inscribing after QRS, no voltage cutoff) + early potentials (EP = fragmented <1.5 mV) Pace-match 2) PES 3) Activation mapping 4) PES after substrate ablation	1) Ablation mappable VT 2) Ablation of all LP LP present at baseline Endocardium 100/160 pts Epicardium 19/32 pts	1) Abolition of all LP — achieved at endocardium in 79 pts (49%), at epicardium 12/32 pts (37%) 2) Noninducibility of any VT — achieved in 88%	RF time endocardial median ≈25 min epicardial ≈6 min Procedure time Median 210–270 min Complications 3.1% In-hospital mortality 2.5%	VT recurrence 32% after median 82 (16–192) days VT recurrence according to endpoint 1+2 achieved (16.4%) Endpoint 2 achieved (46%) No endpoint achieved (47.4%)
Wolf et al. (2018) [343] One center observational	159	34 ± 11	25%	1) Post-MI 2) First VT ablation 3) Recurrent, AAD refractory episodes VT	Endocardial Combined endoepicardial 27% — Epicardial access was encouraged — Epicardial ablation 27/46 pts 3.5-mm tip (70 pts) Multielectrode catheters (89 pts)	1) PES 2) Activation mapping 3) Substrate mapping: BV mapping (<1.5 mV) + LAVA (=sharp high-frequency EGMs, possibly of low amplitude, distinct from the far-field EGM occurring anytime during or after the far-field EGM 4) PES	1) Ablation of mappable VT 2) Ablation of LAVA (until local no capture) LAVA present at baseline Endocardium 141/157 pts Epicardium 36/46 pts	1) Abolition of LAVA — achieved in 93/146 pts (64%) 2) Noninducibility — achieved in 94/110 tested pts	RF time 36 ± 20 min Procedure time 250 ± 78 min Complications 7.5% (4 surgical interventions) Procedure-related mortality 1.3%	VT-free survival 55% during 47 months (33–82) Outcome according to endpoints: LAVA abolished vs not abolished 63% vs 44% VT-free survival at 1 year 73%
Berruezo et al. (2015) [344] One center observational	101 Post-MI 75	36 ± 13	—	1) Scar-related VT	Endocardial Combined endoepicardial (27/101 pts, among post-MI not provided) — Endo no substrate/suggestive epi — CE-MRI — VT ECG 3.5-mm tip	1) Substrate mapping: BV (<1.5 mV) + EGMs with delayed components: identification of entrance (shortest delay) of conducting channels 2) PES 3) Activation mapping + pace-match	1) Scar dechanneling targeting entrance 2) Short linear lesions (eg, between scar and mitral annulus) 3) Ablation of VT-related sites — performed in 45%	1) Scar dechanneling — Achieved in 85 pts (84.2%) — Noninducible after 1) 55 pts (54.5%) 2) Noninducibility —achieved in 78%	RF time 24 ± 10 min only scar dechanneling (31 ± 18 min + additional RFCA) Procedure time 227 ± 69 min Complications 6.9% No death	VT recurrence 27% after a median follow-up of 21 months (11–29) 1-year VT-free survival according to endpoint: scar dechanneling complete vs incomplete (≈82% vs ≈65%)
Porta-Sánchez et al. (2018) [345] Multicenter observational	20	33 ± 11	—	1) Post-MI 2) Recurrent VT	Endocardial 3.5-mm tip 4 pts Multielectrode catheters 16 pts	1) Substrate mapping: annotation of LP (=fractionated/isolated after QRS offset) and assessment if LP showed additional delay of >10 ms after RV extrastimuli (S1 600 ms, S2 VERP + 20 ms) defined as DEEP 2) PES 3) Additional mapping	1) Targeting areas with DEEP 2) Ablation of VT-related sites discretion of operator	1) Noninducibility— achieved in 80% after DEEP ablation — Remains 80% after additional ablation in those inducible	RF time 30.6 ± 21.4 min Procedure time and complications not reported	VT recurrence 25% at 6-month follow-up
de Riva et al. (2018) [346] One center observational	60	33 ± 12	30%	1) Post-MI 2) Sustained VT	Endocardial Epicardial 10% — Endocardial failure — Epicardial substrate suspected 3.5-mm tip catheter	1) PES 2) Substrate mapping: systematic assessment of presumed infarct area independent of BV during SR and RV extrastimuli Pacing (S1 500 ms, S2 VRP + 50ms): EDP (evoked delayed potentials) = low voltage (<1.5 mV) EGM with conduction delay >10 ms or block in response to S2 3) Activation and pace mapping	1) Targeting EDPs only 2) Ablation of VT-related sites based on activation/pace mapping	1) Elimination of EDPs — achieved in all 2) Noninducibility of targeted VT (fast VT with VTCL≈VERP not targeted) — Achieved in 67% after EDP ablation — Achieved in 90% after additional ablation	RF time 15 min (10–21) Procedure time 173 min (150–205) Complications 3.3% One procedure-related death	VT recurrence 22% at median follow-up of 16 months (8–23) Subgroup of patients with EDPs in normal-voltage areas at baseline (hidden substrate) compared to historical matched group without EDP mapping VT-free survival at 1 year 89% vs 73%

Included studies: post myocardial infarction (or data for patients post myocardial infarction provided)

AAD antiarrhythmic drug, BV bipolar voltage, BZ border zone, CABG coronary artery bypass grafting, CE-MRI contrast-enhanced magnetic resonance imaging, DC delayed component, DEEP decremental evoked potential, ECG electrocardiogram, EDP evoked delayed potential, EF ejection fraction, EGM electrogram, ICD implantable cardioverter defibrillator, LAVA local abnormal ventricular activity, MI myocardial infarction, PEA pulseless electrical activity, PES programmed electrical stimulation, pts patients, PVC premature ventricular complex, RCT randomized controlled trial, RF radiofrequency, RFCA radiofrequency catheter ablation, RV right ventricle, SHD structural heart disease, SR sinus rhythm, VT ventricular tachycardia

Table 8

Catheter ablation of ventricular arrhythmias in cardiac sarcoidosis

Study	N	LVEF, %	Concurrent immunosuppressive therapy, n (%)	VTs induced, mean ± SD	Mapping, Endo n/Epi n	Ablation, Endo n/Epi n	Patients undergoing repeated procedures, n (%)	VT Recurrence, n (%)	VT Burden decrease, n (%)	Major complications	Follow-up, months
Koplan et al. [347]	8	35 ± 15	5 (63)	4 ± 2	6/2	8/2	1 (13)	6 (75)	4 (44)	NR	6
Jefic et al. [174]	9	42 ± 14	8 (89)	5 ± 7	8/1	NR	3 (33)	4 (44)	9 (100)	NR	20
Naruse et al. [175]	14	40 ± 12	12 (86)	3 ± 1	14/0	14/0	4 (29)	6 (43)	NR	NR	33
Dechering et al. [348]	8	36 ± 19	NR	4 ± 2	NR	NR	NR	1 (13)	7 (88)	NR	6
Kumar et al. [176]	21	36 ± 14	12 (57)	Median 3 (range 1–8)	21/8	21/5	11 (52)	15 (71)	16 (76)	4.7%	24
Muser et al. [177]	31	42 ± 15	22 (71)	Median 3 (range 1–5)	31/11	31/8	9 (29)	16 (52)	28 (90)	4.5%	30

LVEF left ventricular ejection fraction, N number, NR not reported, VT ventricular tachycardia

9.1 Ablation Power Sources and Techniques

Key Points

An impedance drop ≥10 ohms or a contact force ≥10 g is commonly used as a target for radiofrequency energy delivery.
The use of half normal saline generates larger ablation lesions but can result in steam pops.
Simultaneous bipolar or unipolar ablation can result in larger ablation lesions.
Cryoablation can be beneficial for achieving more stable contact on the papillary muscles.
Ethanol ablation can generate lesions in areas where the arrhythmogenic substrate cannot be otherwise reached, provided that suitable target vessels are present.
Stereotactic radiotherapy is an emerging alternative to ablation, requiring identification of a region of interest that can be targeted prior to the radiation treatment.

9.2 Idiopathic Outflow Tract Ventricular Arrhythmia

Key Points

The RVOT, pulmonary arteries, SVs, LV epicardium and endocardium contain most of the outflow tract arrhythmias.
Activation mapping and pace mapping can be used to guide ablation in the RVOT.
Imaging of coronary artery ostia is essential before ablation in the aortic SVs.
The LV summit is a challenging site of origin, often requiring mapping and/or ablation from the RVOT, LVOT, SVs, coronary venous system, and sometimes the epicardial space.
Deep intraseptal VA origins can be challenging to reach.

9.3 Idiopathic Nonoutflow Tract Ventricular Arrhythmia

Key Points

VAs originating from the papillary muscles can be challenging due to multiple morphologies of the VA and the difficulty in achieving and maintaining sufficient contact during ablation.
VAs originate in LV papillary muscles more often than in RV papillary muscles; they more often originate from the posteromedial than the anterolateral papillary muscle and occur more often at the tip than at the base.
Pace mapping is less accurate than in other focal VAs.
ICE is particularly useful for assessing contact and stability.
Cryoablation can also aid in catheter stability during lesion delivery.

9.4 Bundle Branch Reentrant Ventricular Tachycardia and Fascicular Ventricular Tachycardia

Key Points

Bundle branch reentry can occur in a variety of patients in whom the conduction system can be affected, including patients with dilated cardiomyopathy (DCM), valvular heart disease, myocardial infarction, myotonic dystrophy, Brugada syndrome, and ARVC, among others.
Ablation of either the right or left bundle branch eliminates bundle branch reentrant ventricular tachycardia (BBRVT) but does not eliminate other arrhythmic substrates.
A correct diagnosis of BBRVT is crucial and should employ established criteria prior to ablation of either of the bundle branches.
Ablation of the AV node does not cure BBRVT.
Ablation of either bundle branch does not cure interfascicular VT.
For posterior fascicular VTs, the P1 potential is targeted during VT; if P1 cannot be identified or VT is not tolerated, an anatomical approach can be used.
Purkinje fibers can extend to the papillary muscles, and these can be part of the VT circuit.
For anterior fascicular VTs, the P1 potential is targeted with ablation.
Focal nonreentrant fascicular VT is infrequent and can occur in patients with IHD; however, it cannot be induced with programmed stimulation, and the target is the earliest Purkinje potential during VT.

9.5 Postinfarction Ventricular Tachycardia

Key Points

In cases of multiple inducible VTs, the clinical VT should be preferentially targeted.
Elimination of all inducible VTs reduces VT recurrence and is associated with prolonged arrhythmia-free survival.
For tolerated VTs, entrainment mapping allows for focal ablation of the critical isthmus.
For nontolerated VTs, various ablation strategies have been described, including targeting abnormal potentials, matching pace mapping sites, areas of slow conduction, linear lesions, and scar homogenization.
Imaging can be beneficial in identifying the arrhythmogenic substrate.
Epicardial ablation is infrequently required, but epicardial substrate is an important reason for VT recurrence after VT ablation in patients with prior infarcts.

9.6 Dilated Cardiomyopathy

Key Points

Identifying the location and extent of scarring on CMR is beneficial in procedural planning and has improved the outcomes of ablation in patients with DCM.
The ablation strategy is similar to postinfarction VT.
An intramural substrate is more frequently encountered in DCM than in postinfarction patients and requires a different ablation strategy than for patients with either epicardial or endocardial scarring.
Epicardial ablation is beneficial if the scar is located in the epicardium of the LV free wall.
For intramural circuits involving the septum, epicardial ablation is not beneficial.
In the absence of CMR, unipolar voltage mapping has been described as a method to indicate a deeper-seated scar.

9.7 Ventricular Tachycardia Ablation in Hypertrophic Cardiomyopathy

Key Points

Polymorphic VT and VF are the most common VAs in HCM; monomorphic VT is less common.
The arrhythmogenic substrate in HCM often involves the septum but can extend to the epicardium, often necessitating combined endocardial and epicardial ablation procedures to eliminate the VT.
VT associated with apical aneurysms is often ablated endocardially.

9.8 Brugada Syndrome

Key Points

PVC-triggered VF or polymorphic VT are the most prevalent VAs that motivate device therapy in patients with Brugada syndrome.
Monomorphic VT is less frequent but can be caused by BBRVT in patients with Brugada syndrome.
The arrhythmogenic substrate is located in the RV epicardium and can be demonstrated by sodium channel blockers.
Ablation targets include fractionated prolonged electrograms on the epicardial aspect of the RV.

9.9 Polymorphic Ventricular Tachycardia/Ventricular Fibrillation Triggers

Key Points

Recurrent PVC-induced VF is most often triggered by PVCs originating from Purkinje fibers, located in the RVOT, the moderator band, or the LV.
Patients with a single triggering PVC are better ablation candidates; however, there are often multiple triggers.
Patients with healed myocardial infarction often require extensive ablation of the Purkinje fiber system within or at the scar border.
Ischemia should be ruled out as a trigger for VF prior to ablation.

9.10 Arrhythmogenic Right Ventricular Cardiomyopathy

Key Points

The arrhythmogenic substrate in ARVC is located in the epicardium and can involve the endocardium in advanced stages.
The most commonly affected areas are the subtricuspid and RV outflow regions.
LV involvement is not uncommon.
Endocardial-epicardial ablation is often required and results in higher acute success and lower recurrence rates compared with endocardial ablation alone.
Conventional mapping and ablation techniques, including entrainment mapping of tolerated VT, pace mapping, and substrate ablation, are used.

9.11 Mapping and Ablation in Congenital Heart Disease

Key Points

Patients with a VT substrate after congenital heart defect surgery include those with repaired tetralogy of Fallot, repaired ventricular septal defect, and repaired d-transposition of the great arteries (D-TGA), as well as Ebstein’s anomaly among other disease processes.
VT isthmuses are often located between anatomical barriers and surgical incisions or patch material.
An anatomical isthmus can be identified and targeted during sinus rhythm.
For tolerated VTs, entrainment mapping is the method of choice for identifying critical components of the reentry circuit.

9.12 Sarcoidosis

Key Points

The arrhythmogenic substrate in cardiac sarcoidosis is often intramurally located but can include the endocardium and epicardium.
A CMR is beneficial in planning an ablation procedure in cardiac sarcoidosis.
The arrhythmogenic substrate can be complex and can include areas of active inflammation and chronic scarring.
The VT recurrence rate after ablation is high.

9.13 Chagas Disease

Key Points

The pathogenesis of Chagas disease is poorly understood but often results in an inferolateral LV aneurysm.
The arrhythmogenic substrate is located intramurally and on the epicardial surface, often necessitating an epicardial ablation procedure.

9.14 Miscellaneous Diseases and Clinical Scenarios With Ventricular Tachycardia

Key Points

Lamin cardiomyopathy often has a poor prognosis, progressing to end-stage heart failure.
VT ablation is challenging due to intramural substrates
VT recurrence rate is high after ablations.
VT in patients with noncompaction tends to originate from regions of noncompacted myocardium where scar can be identified in the midapical LV.
VT ablation in patients with LV assist device can be challenging due to the limitation of preprocedural imaging, and the electromagnetic noise generated by the LV assist device.

9.15 Surgical Therapy

Key Points

Surgery-facilitated access to the epicardium via a limited subxiphoid incision can be helpful in the case of adhesions.
Cryoablation via thoracotomy is possible for posterolateral substrates and via sternotomy for anterior substrates.

9.16 Sympathetic Modulation

Key Points

Sympathetic modulation targeting the stellate ganglia by video-assisted thoracoscopy may be considered for failed VT ablation procedures or VF storms.
A temporary effect can be obtained with the percutaneous injection or infusion of local anesthetics.

9.17 Endpoints of Catheter Ablation of Ventricular Tachycardia

Key Points

Noninducibility of VT by PES after ablation is a reasonable endpoint and predictor for VT recurrence after VT ablation in patients with SHD.
Due to the limitations of programmed stimulation, endpoints other than noninducibility have been described, including elimination of excitability, elimination of late potentials or local abnormal ventricular activity, dechanneling, substrate homogenization, core isolation, image-guided ablation, and anatomically fixed substrate ablation.

10 Postprocedural Care

Access-related issues, anticoagulation (Table 9), and complications (Table 10), as well as the management thereof, are reviewed in this section. Furthermore, assessment of outcomes and determinants of outcomes are detailed (Fig. 13).

Table 9

Postprocedural care in prospective studies of ventricular tachycardia catheter ablation

Study	Postprocedure NIPS	AAD type	AAD duration	Follow-up	ICD programming	Anticoagulation postablation	Bleeding and thromboembolic events (ablation arm)
Calkins 2000 [349]	No	Patients were continued on the type of antiarrhythmic therapy they had received before ablation.	At least the first 3 months after hospital discharge	Evaluation at 1, 3, 6, 9, 12, and 24 months after ablation	Not specified	Not specified	Four of 146 (2.7%) stroke or TIA, 4 (2.7%) episodes of pericardial tamponade
SMASH-VT 2007 [154]	No	No patient received an AAD (other than beta blockers) before the primary endpoint was reached.	N/A	Followed in the ICD clinic at 3, 6, 9, 12, 18, and 24 months; echocardiography at 3 and 12 months	Not specified	Oral anticoagulation 4–6 weeks, aspirin if fewer than 5 ablation lesions	One pericardial effusion without tamponade, managed conservatively; 1 deep venous thrombosis
Stevenson 2008 [146]	No	The previously ineffective AAD was continued for the first 6 months, after which time drug therapy was left to the discretion of the investigator.	Six months, after which time drug therapy was left to the discretion of the investigator	Echocardiogram and neurologist examination before and after ablation; office visit at 2 and 6 months, with ICD interrogation where applicable	Not specified	Three months with either 325 mg/day aspirin or warfarin if ablation had been performed over an area over 3 cm in length	Vascular access complications in 4.7%; no thromboembolic complications
Euro-VT 2010 [147]	No	Drug management during follow-up was at the discretion of the investigator.	Drug management during follow-up was at the discretion of the investigator.	At 2, 6, and 12 months, with ICD interrogation where applicable	Investigators were encouraged to program ICD detection for slow VT for at least 20 beats or 10 seconds to allow nonsustained VT to terminate before therapy is triggered.	Not specified	No major bleeding or thromboembolic complications
VTACH 2010 [155]	No	Discouraged	Discouraged	Every 3 months from ICD implantation until completion of the study	VF zone with a cutoff rate of 200–220 bpm and a VT zone with a cutoff CL of 60 ms above the slowest documented VT and ATP followed by shock	Not specified	One transient ischemic ST-segment elevation; 1 TIA
CALYPSO 2015 [156]	No	Discouraged	Discouraged	At 3 and 6 months	Investigators were required to ensure that VT detection in the ICD is programmed at least 10 beats below the rate of the slowest documented VT.	At the discretion of the treating physician, anticoagulation recommended with aspirin or warfarin for 6–12 weeks
Marchlinski 2016 [148]	Not required	Not dictated by the study protocol	Not dictated by the study protocol	At 6 months and at 1, 2, and 3 years	Not dictated by the study protocol	Per clinical conditions and physician preference	Cardiac perforation (n = 1), pericardial effusion (n = 3)
VANISH 2016 [145]	No	Continued preprocedure antiarrhythmic medications	Not specified	A 3-month office visit, echo, ICD check; a 6-month office visit, ICD check; every 6 months thereafter, an office visit, ICD check	VT detection at 150 bpm or with a 10–20 bpm margin if the patient was known to have a slower VT. ATP was recommended in all zones. The protocol was modified to recommend prolonged arrhythmia detection duration for all patients.	Intravenous heparin (without bolus) 6 hours after sheath removal, then warfarin if substrate-mapping approach used or if more than 10 minutes of RF time	Major bleeding in 3 patients; vascular injury in 3 patients; cardiac perforation in 2 patients
SMS 2017 [157]	No	At the discretion of the investigator	At the discretion of the investigator	At 3, 6, 9, and 12 months, and at 3- or 6-month intervals until completion of the study or until 33-month follow-up was reached	VF zone at 200–220 bpm, detection 18 of 24 beats, shock only; VT zone detection at least 16 consecutive beats, ATP, and shocks. Where VT rates were exclusively >220 bpm, VT zone at 160–180 bpm was recommended; where VT rates were <220 bpm, VT zone with a CL 60 ms above the slowest VT was recommended	Aspirin (250 mg/day) or warfarin as necessitated by the underlying heart disease	Two tamponades requiring pericardiocentesis

AAD antiarrhythmic dug, ATP antitachycardia pacing, CL cycle length, ICD implantable cardioverter defibrillator, NIPS noninvasive programmed stimulation, RF radiofrequency, TIA transient ischemic attack, VF ventricular fibrillation, VT ventricular tachycardia

10.1 Postprocedural Care: Access, Anticoagulation, Disposition

10.1.1 Postprocedural Care: Access

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabx_HTML.png

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Taby_HTML.png

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabz_HTML.png

10.1.2 Postprocedural Care: Anticoagulation

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabaa_HTML.png

10.2 Incidence and Management of Complications

Table 10

Major complications of ventricular arrhythmia ablation in patients with structural heart disease

Complication	Incidence	Mechanisms	Presentation	Prevention	Treatment	Ref.
In-hospital mortality	0%–3%	VT recurrence, heart failure, complications of catheter ablation	Not applicable	Correct electrolyte disturbances and optimize medical status before ablation	—	[146, 154, 155, 300, 350]
Long-term mortality	3%–35% (12–39 months of follow-up)	VT recurrence and progression of heart failure	Cardiac nonarrhythmic death (heart failure) and VT recurrence	Identification of patients with indication for heart transplantation	—	[146, 154, 155, 300]
Neurological complication (stroke, TIA, cerebral hemorrhage)	0%–2.7%	Emboli from left ventricle, aortic valve, or aorta; cerebral bleeding	Focal or global neurological deficits	Careful anticoagulation control; ICE can help detection of thrombus formation, and of aortic valve calcification; TEE to assess aortic arch	Thrombolytic therapy	[146, 154, 155, 300, 350]
Pericardial complications: cardiac tamponade, hemopericardium, pericarditis	0%–2.7%	Catheter manipulation, RF delivery, epicardial perforation	Abrupt or gradual fall in blood pressure; arterial line is recommended in ablation of complex VT	Contact force can be useful, careful in RF delivery in perivenous foci and RVOT	Pericardiocentesis; if necessary, surgical drainage, reversal heparin; steroids and colchicine in pericarditis	[146, 154, 155, 300, 350]
AV block	0%–1.4%	Energy delivery near the conduction system	Fall in blood pressure and ECG changes	Careful monitoring when ablation is performed near the conduction system; consider cryoablation	Pacemaker; upgrade to a biventricular pacing device might be necessary	[146, 154, 300, 350]
Coronary artery damage/MI	0.4%–1.9%	Ablation near coronary artery, unintended coronary damage during catheter manipulation in the aortic root or crossing the aortic valve	Acute coronary syndrome; confirmation with coronary catheterization	Limit power near coronary arteries and avoid energy delivery <5 mm from coronary vessel; ICE is useful to visualize the coronary ostium	Percutaneous coronary intervention	[146, 154, 155, 300, 350]
Heart failure/pulmonary edema	0%–3%	External irrigation, sympathetic response due to ablation, and VT induction	Heart failure symptoms	Urinary catheter and careful attention to fluid balance and diuresis, optimize clinical status before ablation, reduce irrigation volume if possible (decrease flow rates or use closed irrigation catheters)	New/increased diuretics	[146, 154, 155, 300]
Valvular injury	0%–0.7%	Catheter manipulation, especially retrograde crossing the aortic valve and entrapment in the mitral valve; energy delivery to subvalvular structures, including papillary muscle	Acute cardiovascular collapse, new murmurs, progressive heart failure symptoms	Careful catheter manipulation; ICE can be useful for identification of precise location of energy delivery	Echocardiography is essential in the diagnosis; medical therapy, including vasodilators and dobutamine before surgery; IABP is useful in acute mitral regurgitation and is contraindicated in aortic regurgitation	[146, 154, 155, 300]
Acute periprocedural hemodynamic decompensation, cardiogenic shock	0%–11%	Fluid overloading, general anesthesia, sustained VT	Sustained hypotension despite optimized therapy	Close monitoring of fluid infusion and hemodynamic status -Optimize medical status before ablation -pLVAD -Substrate mapping preferred, avoid VT induction in higher-risk patients	Mechanical HS	[146, 154, 155, 300, 351]
Vascular injury: hematomas, pseudoaneurysm, AV fistulae	0%–6.9%	Access to femoral arterial and catheter manipulation	Groin hematomas, groin pain, fall in hemoglobin	Ultrasound-guided access	Ultrasound-guided compression, thrombin injection, and surgical closure	[146, 154, 155, 300, 350]
Overall major complications with SHD	3.8%–11.24%					[146, 154, 155, 300, 350]
Overall all complications	7%–14.7%					[300, 352, 353]

AV atrioventricular, ECG electrocardiogram, HS hemodynamic support, IABP intra-aortic balloon pump, ICE intracardiac echocardiography, MI myocardial infarction, pLVAD percutaneous left ventricular assist device, RF radiofrequency, RVOT right ventricular outflow tract, SHD structural heart disease, TEE transesophageal echocardiography, TIA transient ischemic attack, VT ventricular tachycardia

10.3 Hemodynamic Deterioration and Proarrhythmia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabab_HTML.png

10.4 Follow-up of Patients Post Catheter Ablation of Ventricular Tachycardia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabac_HTML.png

11 Training and Institutional Requirements and Competencies

This section contains the general training and institutional requirements with an emphasis on lifelong learning, professionalism, and acquisition and maintenance of knowledge and skills. In addition, institutional requirements for specific procedures are reviewed.

11.1 Training Requirements and Competencies for Catheter Ablation of Ventricular Arrhythmias

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabad_HTML.png

11.2 Institutional Requirements for Catheter Ablation of Ventricular Tachycardia

https://static-content.springer.com/image/art%3A10.1007%2Fs10840-019-00664-2/MediaObjects/10840_2019_664_Tabae_HTML.png

12 Future Directions

This section summarizes ongoing trials and the need for prospective evaluation of different clinical problems. It further reviews recent advances and limitations of various mapping techniques and addresses unanswered questions requiring future investigations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen ²

Appendix

Appendix 1

Author disclosure table

Writing group member	Employment	Honoraria/Speaking/Consulting	Speakers’ bureau	Research^*	Fellowship support^*	Ownership/Partnership/Principal/Majority stockholder	Stock or stock options	Intellectual property/Royalties	Other
Edmond M. Cronin, MB, BCh, BAO, FHRS, CCDS, CEPS-A (Chair)	Hartford Hospital, Hartford, Connecticut	None	None	None	None	None	None	None	None
Frank M. Bogun, MD (Vice-Chair)	University of Michigan, Ann Arbor, Michigan	None	None	None	None	None	None	None	None
Philippe Maury, MD (EHRA Chair)	University Hospital Rangueil, Toulouse, France	None	None	None	None	None	None	None	None
Petr Peichl, MD, PhD (EHRA Vice-Chair)	Institute for Clinical and Experimental Medicine, Prague, Czech Republic	1: Abbott; 1: Biosense Webster; 1: BIOTRONIK	None	None	None	None	None	None	None
Minglong Chen, MD, PhD, FHRS (APHRS Chair)	Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China	None	None	None	None	None	None	None	0: APHRS Board Member
Narayanan Namboodiri, MBBS, MD (APHRS Vice-Chair)	Sree Chitra Institute for Medical Sciences and Technology, Thiruvananthapuram, India	None	None	None	None	None	None	None	None
Luis Aguinaga, MD, PhD, FESC, FACC (LAHRS Chair)	Centro Privado de Cardiología, Tucuman, Argentina	None	None	None	None	None	None	None	None
Luiz Roberto Leite, MD, PhD, FHRS (LAHRS Vice-Chair)	Instituto Brasília de Arritmia, Brasília, Brazil	None	1: Boehringer Ingelheim	None	None	None	None	None	None
Sana M. Al-Khatib, MD, MHS, FHRS, CCDS	Duke University Medical Center, Durham, North Carolina	None	None	None	None	None	None	None	None
Elad Anter, MD	Beth Israel Deaconess Medical Center, Boston, Massachusetts	2: Itamar Medical; 3: Boston Scientific; 4: Biosense Webster	None	None	None	None	None	None	None
Antonio Berruezo, MD, PhD	Heart Institute, Teknon Medical Center, Barcelona, Spain	1: Biosense Webster	1: Biosense Webster	2: Biosense Webster	None	None	None	None	None
David J. Callans, MD, FHRS, CCDS	University of Pennsylvania, Philadelphia, Pennsylvania	1: Abbott Laboratories; 1: BIOTRONIK; 1: Medtronic; 1: Wolters Kluwer; 2: Boston Scientific	None	4: NIH	2: BIOTRONIK; 2: Boston Scientific; 4: Abbott; 4: Biosense Webster; 4: Medtronic	None	None	None	1: Acutus Medical; 1: AtriCure; 1: Impulse Dynamics; 1: Thermedical; 3: Bayer
Mina K. Chung, MD, FHRS	Cleveland Clinic, Cleveland, Ohio	2: ABIM	None	5: AHA; 5: NIH	None	None	None	1: Elsevier; 1: Up to Date	0: ACC (EP Section Leadership Council member); 0: AHA (Chair, ECG & Arrhythmias Committee; Member, Clinical Cardiology Leadership Committee; Member, Committee on Scientific Sessions Programming); 0: Amarin (Data monitoring committee member); 0: BIOTRONIK; 2: AHA (Associate Editor, Circulation Arrhythmia & Electrophysiology)
Phillip Cuculich, MD	Washington University School of Medicine, St. Louis, Missouri	2: Medtronic	None	None	None	None	None	None	None
Andre d’Avila, MD, PhD	Hospital Cardiologico SOS Cardio, Florianopolis, Brazil	None	None	None	None	None	None	None	None
Barbara J. Deal, MD, FACC	Northwestern University Feinberg School of Medicine, Chicago, Illinois	None	None	None	None	None	None	None	None
Paolo Della Bella, MD	Ospedale San Raffaele, Milan, Italy	2: Biosense Webster; 2: Boston Scientific; 3: Abbott	None	None	2: Medtronic; 3: Abbott Vascular; 3: Biosense Webster; 3: BIOTRONIK; 4: Boston Scientific	None	None	None	None
Thomas Deneke, MD, PhD, FHRS	Herz- und Gefäß-Klinik, Bad Neustadt, Germany	None	None	None	None	None	None	None	None
Timm-Michael Dickfeld, MD, PhD, FACC, FHRS	University of Maryland, Baltimore, Maryland	1: Abbott Laboratories; 1: Biosense Webster; 1: Impulse Dynamics; 1: Philips	None	1: GE Healthcare	None	None	None	None	None
Claudio Hadid, MD	Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina	None	None	None	None	None	None	None	None
Haris M. Haqqani, MBBS, PhD, FHRS	University of Queensland, The Prince Charles Hospital, Chermside, Australia	0: Abbott Laboratories; 0: Boston Scientific; 0: Medtronic	None	3: Biosense Webster	None	None	None	None	None
G. Neal Kay, MD, CCDS	University of Alabama at Birmingham, Birmingham, Alabama	None	None	None	None	None	None	None	None
Rakesh Latchamsetty, MD, FHRS	University of Michigan, Ann Arbor, Michigan	None	1: BIOTRONIK	None	None	None	None	None	None
Francis Marchlinski, MD, FHRS	University of Pennsylvania, Philadelphia, Pennsylvania	1: Abbott; 1: Biosense Webster; 1: Boston Scientific; 1: Medtronic; 2: BIOTRONIK	None	1: Abbott; 4: Biosense Webster	2: BIOTRONIK; 2: Boston Scientific; 4: Abbott; 4: Biosense Webster; 4: Medtronic	None	None	None	None
John M. Miller, MD, FHRS	Indiana University School of Medicine, Krannert Institute of Cardiology, Indianapolis, Indiana	1: Abbott Laboratories; 1: Biosense Webster; 1: Boston Scientific; 1: BIOTRONIK; 1: Medtronic	None	None	3: Biosense Webster; 3: Boston Scientific; 3: Medtronic	None	None	1: Elsevier	None
Akihiko Nogami, MD, PhD	University of Tsukuba, Ibaraki, Japan	1: Abbott Laboratories	None	4: Medtronic	None	None	None	None	None
Akash R. Patel, MD, FHRS, CEPS-P	University of California San Francisco Benioff Children’s Hospital, San Francisco, California	None	None	None	None	None	None	None	None
Rajeev Kumar Pathak, MBBS, PhD, FHRS	Australian National University, Canberra Hospital, Canberra, Australia	1: BIOTRONIK	1: Medtronic	None	None	None	None	None	None
Luis C. Saenz Morales, MD	CardioInfantil Foundation, Cardiac Institute, Bogota, Columbia	None	None	None	None	None	None	None	None
Pasquale Santangeli, MD, PhD	University of Pennsylvania, Philadelphia, Pennsylvania	1: Abiome; 1: Baylis Medical; 1: Biosense Webster; 1: Medtronic; 1: Stereotaxis; 2: Abbott Laboratories	None	None	None	None	None	None	None
John L. Sapp, Jr., MD, FHRS	Queen Elizabeth II Health Sciences Centre, Halifax, Canada	1: Abbott Vascular; 1: Biosense Webster; 1: Medtronic	None	4: Abbott Vascular; 5: Biosense Webster	None	None	None	1: Biosense Webster	None
Andrea Sarkozy, MD, PhD, FEHRA	University Hospital Antwerp, University of Antwerp, Antwerp, Belgium	1: Biosense Webster; 1: BIOTRONIK	None	None	None	None	None	None	0: EHRA Board member
Kyoko Soejima, MD	Kyorin University School of Medicine, Tokyo, Japan	2: Abbott Laboratories; 2: Boehringer Ingelheim	3: Medtronic	None	None	None	None	None	None
William G. Stevenson, MD, FHRS	Vanderbilt University Heart and Vascular Center, Nashville, Tennessee	1: Abbott; 1: BIOTRONIK; 1: Boston Scientific; 1: Medtronic	None	None	None	None	None	0: Biosense Webster; 0: Brigham and Women’s Hospital	None
Usha B. Tedrow, MD, MS, FHRS	Brigham and Women’s Hospital, Boston, Massachusetts	1: Abbott; 1: Biosense Webster; 1: Medtronic	None	None	None	None	None	None	None
Wendy S. Tzou, MD, FHRS	University of Colorado Denver, Aurora, Colorado	1: Abbott; 1: Biosense Webster; 1: BIOTRONIK; 1: Boston Scientific; 1: Medtronic	None	None	None	None	None	None	None
Niraj Varma, MD, PhD	Cleveland Clinic, Cleveland, Ohio	1: BIOTRONIK; 1: Medtronic	None	3: Abbott	None	None	None	None	None
Katja Zeppenfeld, MD, PhD, FESC, FEHRA	Leiden University Medical Center, Leiden, the Netherlands	1: Abbott	None	5: Biosense Webster	3: Biosense Webster	None	None	None	None

Number value: 0 = $0; 1 = ≤ $10,000; 2 = > $10,000 to ≤ $25,000; 3 = > $25,000 to ≤ $50,000; 4 = > $50,000 to ≤ $100,000; 5 = > $100,000.

ABIM American Board of Internal Medicine, ACC American College of Cardiology, AHA American Heart Association, APHRS Asia Pacific Heart Rhythm Society, EHRA European Heart Rhythm Association, LAHRS Latin American Heart Rhythm Society, NIH National Institutes of Health

^*Research and fellowship support are classed as programmatic support. Sources of programmatic support are disclosed but are not regarded as a relevant relationship with industry for writing group members or reviewers.

Appendix 2

Reviewer disclosure table

Peer reviewer	Employment	Honoraria/Speaking/Consulting	Speakers’ bureau	Research^*	Fellowship support^*	Ownership/Partnership/Principal/Majority stockholder	Stock or stock options	Intellectual property/Royalties	Other
Samuel J. Asirvatham, MD, FHRS	Mayo Clinic College of Medicine, Rochester, Minnesota	1: Abbott; 1: BIOTRONIK; 1: Boston Scientific; 1: Medtronic	None	None	None	None	None	1: AliveCor	None
Eduardo Back Sternick, MD, PhD	Faculdade Ciências Médicas de Minas, Gerais, Brazil	None	None	None	None	None	None	None	None
Janice Chyou, MD	Northport VA Medical Center, Northport, New York; Agile Health, New York, New York	None	None	None	None	None	None	None	None
Sabine Ernst, MD, PhD	Royal Brompton and Harefield Hospitals, London, England	2: Biosense Webster; 2: Stereotaxis	None	3: Other; 4: Baylis; 4: Spectrum Dynamics	None	None	None	None	None
Guilherme Fenelon, MD, PhD	Hospital Israelita Albert Einstein, Sao Paulo, Sao Paulo, Brazil	1: Libbs	None	None	None	None	None	None	None
Edward P. Gerstenfeld, MD, MS, FACC	University of California, San Francisco, San Francisco, California	1: Abbott Vascular; 1: Biosense Webster; 1: Boston Scientific; 1: Medtronic	None	4: Abbott Vascular; 4: Biosense Webster	None	None	None	None	None
Gerhard Hindricks, MD	Heart Center Leipzig at the University of Leipzig, Leipzig, Germany	None	None	4: Abbott Vascular	None	None	None	None	None
Koichi Inoue, MD, PhD	Sakurabashi-Watanabe Hospital, Osaka, Japan	2: Biosense Webster; 2: Medtronic Japan	None	None	None	None	None	None	None
Jeffrey J. Kim, MD	Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas	None	None	None	3: Medtronic	None	None	None	None
Kousik Krishnan, MD, FHRS, FACC	Rush University Medical Center, Chicago, Illinois	1: ZOLL	None	None	None	None	None	None	None
Karl-Heinz Kuck, MD, FHRS	Asklepios Klinik St. Georg, Hamburg, Germany	1: Abbott Vascular; 1: Biosense Webster; 1: Boston Scientific; 1: Edwards Lifesciences; 1: Medtronic	None	None	None	None	None	None	None
Martin Ortiz Avalos, MD	Hospital San Angel Inn Universidad, Mexico City, Mexico	None	None	None	None	None	None	None	None
Thomas Paul, MD, FACC, FHRS	Georg August University Medical Center, Gottingen, Germany	None	None	None	None	None	None	None	None
Mauricio I. Scanavacca, MD, PhD	Instituto Do Coracao, Sao Paulo, Brazil	None	None	None	None	None	None	None	None
Roderick Tung, MD, FHRS	The University of Chicago Medicine, Center for Arrhythmia Care, Heart and Vascular Center, Chicago, Illinois	2: Abbott	None	2: Abbott	3: Abbott; 3: Medtronic; 3: Boston Scientific	None	None	None	None
Jamie Voss, MBChB	Middlemore Hospital, Auckland, New Zealand	None	None	None	None	None	None	None	None
Takumi Yamada, MD	University of Alabama at Birmingham, Birmingham, Alabama	1: Nihon Kohden; 2: Abbott; 2: Japan Lifeline	None	None	None	None	None	None	None
Teiichi Yamane, MD, PhD, FHRS	Jikei University School of Medicine, Tokyo, Japan	1: Boehringer Ingelheim; 1: Bristol-Myers Squibb; 2: Abbott Laboratories; 2: Medtronic Japan	None	None	None	None	None	None	None

Number value: 0 = $0; 1 = ≤ $10,000; 2 = > $10,000 to ≤ $25,000; 3 = > $25,000 to ≤ $50,000; 4 = > $50,000 to ≤ $100,000; 5 = > $100,000.

Electronic supplementary material

ESM 1 (PDF 2569 kb)

Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm. 2009;6:886–933.PubMed

Hosseini SM, Rozen G, Saleh A, et al. Catheter ablation for cardiac arrhythmias: utilization and in-hospital complications, 2000 to 2013. JACC Clin Electrophysiol. 2017;3:1240–8.PubMed

Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, et al. A decade of information on the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2017 report from the European Heart Rhythm Association. Europace. 2017;19(Suppl. 2):ii1–ii90.PubMed

Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15:e73–e189.PubMed

Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Europace. 2015;17:1601–87.PubMed

Indik JH, Patton KK, Beardsall M, et al. HRS clinical document development methodology manual and policies: executive summary. Heart Rhythm. 2017;14:e495–500.PubMed

Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;67:1572–4.PubMed

Martinez BK, Baker WL, Konopka A, et al. Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease. Heart Rhythm 2019.

Yamada T, Kay GN. Anatomical consideration in catheter ablation of idiopathic ventricular arrhythmias. Arrhythm Electrophysiol Rev. 2016;5:203–9.PubMedPubMedCentral

10.

Della Bella P, Maccabelli G, Carbucicchio C. Anatomical assessment for catheter ablation of ventricular tachycardia. In: Auricchio A, editor. Cardiac Imaging in Electrophysiology. London: Springer-Verlag; 2012. p. 95–104.

11.

Enriquez A, Malavassi F, Saenz LC, Supple G, Santangeli P, Marchlinski FE, et al. How to map and ablate left ventricular summit arrhythmias. Heart Rhythm. 2017;14:141–8.PubMed

12.

Saremi F, Muresian H, Sanchez-Quintana D. Coronary veins: comprehensive CT-anatomic classification and review of variants and clinical implications. Radiographics. 2012;32:E1–E32.PubMed

13.

Ho SY. Anatomic insights for catheter ablation of ventricular tachycardia. Heart Rhythm. 2009;6(Suppl. 8):S77–80.PubMed

14.

Ho SY, Nihoyannopoulos P. Anatomy, echocardiography, and normal right ventricular dimensions. Heart. 2006;92(Suppl. 1):i2–i13.PubMedPubMedCentral

15.

Sánchez-Quintana D, Ho SY, Climent V, Murillo M, Cabrera JA. Anatomic evaluation of the left phrenic nerve relevant to epicardial and endocardial catheter ablation: implications for phrenic nerve injury. Heart Rhythm. 2009;6:764–8.PubMed

16.

Yamada T, Litovsky SH, Kay GN. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2008;1:396–404.PubMed

17.

McAlpine WA. Heart and Coronary Arteries: An Anatomical Atlas for Clinical Diagnosis, Radiological Investigation, and Surgical Treatment. New York: Springer-Verlag; 1975.

18.

Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991;83:1649–59.PubMed

19.

Wellens HJ, Bar FW, Lie KI. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med. 1978;64:27–33.PubMed

20.

Vereckei A, Duray G, Szenasi G, Altemose GT, Miller JM. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm. 2008;5:89–98.PubMed

21.

Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation. 1988;77:560–8.PubMed

22.

Dixit S, Gerstenfeld EP, Callans DJ, Marchlinski FE. Electrocardiographic patterns of superior right ventricular outflow tract tachycardias: distinguishing septal and free-wall sites of origin. J Cardiovasc Electrophysiol. 2003;14:1–7.PubMed

23.

Callans DJ, Menz V, Schwartzman D, Gottlieb CD, Marchlinski FE. Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol. 1997;29:1023–7.PubMed

24.

Kanagaratnam L, Tomassoni G, Schweikert R, et al. Ventricular tachycardias arising from the aortic sinus of Valsalva: an under-recognized variant of left outflow tract ventricular tachycardia. J Am Coll Cardiol. 2001;37:1408–14.PubMed

25.

Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart Rhythm. 2010;7:725–30.PubMed

26.

Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventricular arrhythmias originating from the anterior papillary muscle in the left ventricle. J Cardiovasc Electrophysiol. 2009;20:866–72.PubMed

27.

Li S, Wang Z, Shan Z, et al. Surface electrocardiography characteristics and radiofrequency catheter ablation of idiopathic ventricular arrhythmias originating from the left infero-septal papillary muscles: differences from those originating from the left posterior fascicle. Europace. 2018;20:1028–34.PubMed

28.

Berruezo A, Mont L, Nava S, Chueca E, Bartholomay E, Brugada J. Electrocardiographic recognition of the epicardial origin of ventricular tachycardias. Circulation. 2004;109:1842–7.PubMed

29.

Daniels DV, Lu YY, Morton JB, et al. Idiopathic epicardial left ventricular tachycardia originating remote from the sinus of Valsalva: electrophysiological characteristics, catheter ablation, and identification from the 12-lead electrocardiogram. Circulation. 2006;113:1659–66.PubMed

30.

Bazan V, Gerstenfeld EP, Garcia FC, et al. Site-specific twelve-lead ECG features to identify an epicardial origin for left ventricular tachycardia in the absence of myocardial infarction. Heart Rhythm. 2007;4:1403–10.PubMed

31.

Valles E, Bazan V, Marchlinski FE. ECG Criteria to identify epicardial ventricular tachycardia in nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol. 2010;3:63–71.PubMed

32.

Bazan V, Bala R, Garcia FC, et al. Twelve-lead ECG features to identify ventricular tachycardia arising from the epicardial right ventricle. Heart Rhythm. 2006;3:1132–9.PubMed

33.

Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic value of the electrocardiogram in patients with syncope: data from the group for syncope study in the emergency room (GESINUR). Heart Rhythm. 2014;11:2035–44.PubMed

34.

Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–8.PubMed

35.

Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2008;156:1196–200.PubMedPubMedCentral

36.

Yoon Y, Ktagawa K, Kato S, et al. Prognostic value of unrecognised myocardial infarction detected by late gadolinium-enhanced MRI in diabetic patients with normal global and regional left ventricular systolic function. Eur Radiol. 2013;23:2101–8.PubMed

37.

Olivotto I, Maron M, Autore C, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52:559–66.PubMed

38.

Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramural scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2013;6:891–7.PubMed

39.

Dweck M, Abgral R, Trivieri M, et al. Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging. 2018;11:94–107.PubMed

40.

Piers SR, Tao Q, van Huls van Taxis CF, Schalij MJ, van der Geest RJ, Zeppenfeld K. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875–83.PubMed

41.

Brugada J, Aguinaga L, Mont L, Betriu A, Mulet J, Sanz G. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol. 2001;37:529–33.PubMed

42.

Nageh M, Kim J, Chen L, Yao JF. Implantable defibrillators for secondary prevention of sudden cardiac death in cardiac surgery patients with perioperative ventricular arrhythmias. J Am Heart Assoc. 2014;3:e000686.PubMedPubMedCentral

43.

Elsokkari I, Parkash R, Gray C, et al. Effect of coronary revascularization on long-term clinical outcomes in patients with ischemic cardiomyopathy and recurrent ventricular arrhythmia. Pacing Clin Electrophysiol. 2018;41:775–9.PubMed

44.

Aquaro GD, Pingitore A, Strata E, Di Bella G, Molinaro S, Lombardi M. Cardiac magnetic resonance predicts outcome in patients with premature ventricular complexes of left bundle branch block morphology. J Am Coll Cardiol. 2010;56:1235–43.PubMed

45.

Yokokawa M, Siontis KC, Kim HM, et al. Value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with frequent premature ventricular complexes undergoing radiofrequency ablation. Heart Rhythm. 2017;14:1695–701.PubMed

46.

Niwano SY, Wakisaka H, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart. 2009;95:1230–7.PubMed

47.

Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2006;133:1426–8.

48.

Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm. 2014;11:e102–65.PubMed

49.

Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2012;9:1737–53.PubMed

50.

Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7:237–43.PubMed

51.

Zhang F, Yang B, Chen H, Ju W, Kojodjojo P, Cao K, et al. Magnetic versus manual catheter navigation for mapping and ablation of right ventricular outflow tract ventricular arrhythmias: a randomized controlled study. Heart Rhythm. 2013;10:1178–83.PubMed

52.

Krittayaphong R, Sriratanasathavorn C, Dumavibhat C, et al. Electrocardiographic predictors of long term outcomes after radiofrequency ablation in patients with right-ventricular outflow tract tachycardia. Europace. 2006;8:601–6.PubMed

53.

Vestal M, Wen MS, Yeh SJ, Wang CC, Lin FC, Wu D. Electrocardiographic predictors of failure and recurrence in patients with idiopathic right ventricular outflow tract tachycardia and ectopy who underwent radiofrequency catheter ablation. J Electrocardiol. 2003;36:327–32.PubMed

54.

Miyazawa K, Ueda M, Kondo Y, Hayashi T, Nakano M, Ishimura M, et al. Rapid mapping and differentiation in ventricular outflow tract arrhythmia using non-contact mapping. J Interv Card Electrophysiol. 2017;49:41–9.PubMed

55.

Akdeniz C, Gul EE, Celik N, Karacan M, Tuzcu V. Catheter ablation of idiopathic right ventricular arrhythmias in children with limited fluoroscopy. J Interv Card Electrophysiol. 2016;46:355–60.PubMed

56.

Morady F, Kadish AH, DiCarlo L, Kou WH, Winston S, deBuitlier M, et al. Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation. 1990;82:2093–9.PubMed

57.

Liao Z, Zhan X, Wu S, et al. Idiopathic ventricular arrhythmias originating from the pulmonary sinus cusp: prevalence, electrocardiographic/electrophysiological characteristics, and catheter ablation. J Am Coll Cardiol. 2015;66:2633–44.PubMed

58.

Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm. 2007;4:863–7.PubMed

59.

Chen H, Shehata M, Swerdlow C, et al. Intramural outflow tract ventricular tachycardia: anatomy, mapping, and ablation. Circ Arrhythm Electrophysiol. 2014;7:978–81.PubMed

60.

Teh AW, Reddy VY, Koruth JS, et al. Bipolar radiofrequency catheter ablation for refractory ventricular outflow tract arrhythmias. J Cardiovasc Electrophysiol. 2014;25:1093–9.PubMed

61.

Lamba J, Redfearn DP, Michael KA, Simpson CS, Abdollah H, Baranchuk A. Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis. Pacing Clin Electrophysiol. 2014;37:73–8.PubMed

62.

Calkins H, Kalbfleisch J, El-Atassi R, Langberg J, Morady F. Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. Am J Cardiol. 1993;71:827–33.PubMed

63.

Rodriguez LM, Smeets JL, Timmermans C, Wellens HJ. Predictors for successful ablation of right- and left-sided idiopathic ventricular tachycardia. Am J Cardiol. 1997;79:309–14.PubMed

64.

Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol. 1994;23:1333–41.PubMed

65.

Wen MS, Yeh SJ, Wang CC, Lin FC, Chen IC, Wu D. Radiofrequency ablation therapy in idiopathic left ventricular tachycardia with no obvious structural heart disease. Circulation. 1994;89:1690–6.PubMed

66.

Movsowitz C, Schwartzman D, Callans DJ, et al. Idiopathic right ventricular outflow tract tachycardia: narrowing the anatomic location for successful ablation. Am Heart J. 1996;131:930–6.PubMed

67.

Frey B, Kreiner G, Fritsch S, Veit F, Gossinger HD. Successful treatment of idiopathic left ventricular outflow tract tachycardia by catheter ablation or minimally invasive surgical cryoablation. Pacing Clin Electrophysiol. 2000;23:870–6.PubMed

68.

Krebs ME, Krause PC, Engelstein ED, Zipes DP, Miles WM. Ventricular tachycardias mimicking those arising from the right ventricular outflow tract. J Cardiovasc Electrophysiol. 2000;11:45–51.PubMed

69.

Kumagai K, Fukuda K, Wakayama Y, et al. Electrocardiographic characteristics of the variants of idiopathic left ventricular outflow tract ventricular tachyarrhythmias. J Cardiovasc Electrophysiol. 2008;19:495–501.PubMed

70.

Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol. 2015;1:116–23.PubMed

71.

Kamakura S, Shimizu W, Matsuo K, et al. Localization of optimal ablation site of idiopathic ventricular tachycardia from right and left ventricular outflow tract by body surface ECG. Circulation. 1998;98:1525–33.PubMed

72.

Yamada T, Yoshida N, Murakami Y, et al. Electrocardiographic characteristics of ventricular arrhythmias originating from the junction of the left and right coronary sinuses of Valsalva in the aorta: the activation pattern as a rationale for the electrocardiographic characteristics. Heart Rhythm. 2008;5:184–92.PubMed

73.

Tada H, Naito S, Ito S, et al. Significance of two potentials for predicting successful catheter ablation from the left sinus of Valsalva for left ventricular epicardial tachycardia. Pacing Clin Electrophysiol. 2004;27:1053–9.PubMed

74.

Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol. 2002;39:500–8.PubMed

75.

Bala R, Garcia FC, Hutchinson MD, et al. Electrocardiographic and electrophysiologic features of ventricular arrhythmias originating from the right/left coronary cusp commissure. Heart Rhythm. 2010;7:312–22.PubMed

76.

Tada H, Nogami A, Naito S, et al. Left ventricular epicardial outflow tract tachycardia: a new distinct subgroup of outflow tract tachycardia. Jpn Circ J. 2001;65:723–30.PubMed

77.

Baman TS, Ilg KJ, Gupta SK, et al. Mapping and ablation of epicardial idiopathic ventricular arrhythmias from within the coronary venous system. Circ Arrhythm Electrophysiol. 2010;3:274–9.PubMed

78.

Carrigan T, Patel S, Yokokawa M, Schmidlin E, Swanson S, Morady F, et al. Anatomic relationships between the coronary venous system, surrounding structures, and the site of origin of epicardial ventricular arrhythmias. J Cardiovasc Electrophysiol. 2014;25:1336–42.PubMed

79.

Santangeli P, Marchlinski FE, Zado ES, et al. Percutaneous epicardial ablation of ventricular arrhythmias arising from the left ventricular summit: outcomes and electrocardiogram correlates of success. Circ Arrhythm Electrophysiol. 2015;8:337–43.PubMed

80.

Nagashima K, Choi EK, Lin KY, et al. Ventricular arrhythmias near the distal great cardiac vein: challenging arrhythmia for ablation. Circ Arrhythm Electrophysiol. 2014;7:906–12.PubMed

81.

Van Herendael H, Garcia F, Lin D, et al. Idiopathic right ventricular arrhythmias not arising from the outflow tract: prevalence, electrocardiographic characteristics, and outcome of catheter ablation. Heart Rhythm. 2011;8:511–8.PubMed

82.

Sadek MM, Benhayon D, Sureddi R, et al. Idiopathic ventricular arrhythmias originating from the moderator band: electrocardiographic characteristics and treatment by catheter ablation. Heart Rhythm. 2015;12:67–75.PubMed

83.

Tada H, Tadokoro K, Miyaji K, et al. Idiopathic ventricular arrhythmias arising from the pulmonary artery: prevalence, characteristics, and topography of the arrhythmia origin. Heart Rhythm. 2008;5:419–26.PubMed

84.

Tada H, Tadokoro K, Ito S, et al. Idiopathic ventricular arrhythmias originating from the tricuspid annulus: prevalence, electrocardiographic characteristics, and results of radiofrequency catheter ablation. Heart Rhythm. 2007;4:7–16.PubMed

85.

Santoro F, DiBiase L, Hranitzky P, et al. Ventricular tachycardia originating from the septal papillary muscle of the right ventricle: electrocardiographic and electrophysiological characteristics. J Cardiovasc Electrophysiol. 2015;26:145–50.PubMed

86.

Sasaki K, Sasaki S, Kimura M, et al. Catheter ablation of ventricular arrhythmias arising from the basal septum of the right ventricle: characteristics and significance of junctional rhythm appearing during ablation. J Interv Card Electrophysiol. 2016;45:159–67.PubMed

87.

Yue-Chun L, Wen-Wu Z, Na-Dan Z, et al. Idiopathic premature ventricular contractions and ventricular tachycardias originating from the vicinity of tricuspid annulus: results of radiofrequency catheter ablation in thirty-five patients. BMC Cardiovasc Disord. 2012;10:12–32.

88.

Yamada T, Yoshida N, Itoh T, Litovsky SH, Doppalapudi H, McElderry HT, et al. Idiopathic ventricular arrhythmias originating from the parietal band: electrocardiographic and electrophysiological characteristics and outcome of catheter ablation. Circ Arrhythm Electrophysiol. 2017;10:e005099.PubMed

89.

Ceresnak SR, Pass RH, Krumerman AK, Kim SG, Nappo L, Fisher JD. Characteristics of ventricular tachycardia arising from the inflow region of the right ventricle. J Electrocardiol. 2012;45:385–90.PubMed

90.

Yamada T, Yoshida N, Litovsky SH, Itoh T, Doppalapudi H, Kay GN. Idiopathic ventricular arrhythmias originating from the infundibular muscles: prevalence, electrocardiographic and electrophysiological characteristics, and outcome of catheter ablation. Circ Arrhythm Electrophysiol. 2018;11:e005749.PubMed

91.

Li T, Zhan XZ, Xue YM, et al. Combined approach improves the outcomes of catheter ablation of idiopathic ventricular arrhythmias originating from the vicinity of tricuspid annulus. Pacing Clin Electrophysiol. 2014;37:624–9.PubMed

92.

Lian-Pin W, Yue-Chun L, Jing-Lin Z, et al. Catheter ablation of idiopathic premature ventricular contractions and ventricular tachycardias originating from right ventricular septum. PLoS One. 2013;8:e67038.PubMedPubMedCentral

93.

Enriquez A, Pathak RK, Santangeli P, et al. Inferior lead discordance in ventricular arrhythmias: a specific marker for certain arrhythmia locations. J Cardiovasc Electrophysiol. 2017;28:1179–86.PubMed

94.

Doppalapudi H, Yamada T, McElderry HT, Plumb VJ, Epstein AE, Kay GN. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. Circ Arrhythm Electrophysiol. 2008;1:23–9.PubMed

95.

Yamada T, Doppalapudi H, McElderry HT, et al. Idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: prevalence, electrocardiographic and electrophysiological characteristics, and results of the radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 2010;21:62–9.PubMed

96.

Yamada T, Doppalapudi H, McElderry HT, et al. Electrocardiographic and electrophysiological characteristics in idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: relevance for catheter ablation. Circ Arrhythm Electrophysiol. 2010;3:324–31.PubMed

97.

Bassil G, Liu CF, Markowitz SM, et al. Comparison of robotic magnetic navigation-guided and manual catheter ablation of ventricular arrhythmias arising from the papillary muscles. Europace. 2018;20(Suppl. 2):ii5–ii10.PubMed

98.

Ban JE, Lee HS, Lee DI, et al. Electrophysiological characteristics related to outcome after catheter ablation of idiopathic ventricular arrhythmia originating from the papillary muscle in the left ventricle. Korean Circ J. 2013;43:811–8.PubMedPubMedCentral

99.

Yokokawa M, Good E, Desjardins B, et al. Predictors of successful catheter ablation of ventricular arrhythmias arising from the papillary muscles. Heart Rhythm. 2010;7:1654–9.PubMedPubMedCentral

100.

Rivera S, Ricapito Mde L, Tomas L, et al. Results of cryoenergy and radiofrequency-based catheter ablation for treating ventricular arrhythmias arising from the papillary muscles of the left ventricle, guided by intracardiac echocardiography and image integration. Circ Arrhythm Electrophysiol. 2016;9:e003874.PubMed

101.

Al’Aref SJ, Ip JE, Markowitz SM, et al. Differentiation of papillary muscle from fascicular and mitral annular ventricular arrhythmias in patients with and without structural heart disease. Circ Arrhythm Electrophysiol. 2015;8:616–24.PubMed

102.

Wasmer K, Köbe J, Dechering DG, et al. Ventricular arrhythmias from the mitral annulus: patient characteristics, electrophysiological findings, ablation, and prognosis. Heart Rhythm. 2013;10:783–8.PubMed

103.

Kumagai K, Yamauchi Y, Takahashi A, et al. Idiopathic left ventricular tachycardia originating from the mitral annulus. J Cardiovasc Electrophysiol. 2005;16:1029–36.PubMed

104.

Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular arrhythmias. J Am Coll Cardiol. 2005;45:877–86.PubMed

105.

Yue-Chun L, Cheng Z, Jun H, Jun-Hua C, Jing-Lin Z, Jia-Feng L. Catheter ablation of idiopathic premature ventricular contractions and ventricular tachycardias originating from the vicinity of endocardial and epicardial mitral annulus. PLoS One. 2013;8:e80777.PubMedPubMedCentral

106.

Yamada T, Doppalapudi H, McElderry HT, Kay GN. Idiopathic mitral annular PVCs with multiple breakouts and preferential conduction unmasked by radiofrequency catheter ablation. Pacing Clin Electrophysiol. 2012;35:e112–5.PubMed

107.

Chen J, Hoff PI, Rossvoll O, et al. Ventricular arrhythmias originating from the aortomitral continuity: an uncommon variant of left ventricular outflow tract tachycardia. Europace. 2012;14:388–95.PubMed

108.

Hai JJ, Chahal AA, Friedman PA, et al. Electrophysiologic characteristics of ventricular arrhythmias arising from the aortic mitral continuity-potential role of the conduction system. J Cardiovasc Electrophysiol. 2015;26:158–63.PubMedPubMedCentral

109.

Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricular arrhythmias originating from the left ventricular summit: anatomic concepts relevant to ablation. Circ Arrhythm Electrophysiol. 2010;3:616–23.PubMed

110.

Mountantonakis SE, Frankel DS, Tschabrunn CM, et al. Ventricular arrhythmias from the coronary venous system: prevalence, mapping, and ablation. Heart Rhythm. 2015;12:1145–53.PubMed

111.

Meininger GR, Berger RD. Idiopathic ventricular tachycardia originating in the great cardiac vein. Heart Rhythm. 2006;3:464–6.PubMed

112.

Yamada T, Doppalapudi H, Litovsky SH, McElderry HT, Kay GN. Challenging radiofrequency catheter ablation of idiopathic ventricular arrhythmias originating from the left ventricular summit near the left main coronary artery. Circ Arrhythm Electrophysiol. 2016;9:e004202.PubMed

113.

Yokokawa M, Latchamsetty R, Good E, et al. Ablation of epicardial ventricular arrhythmias from nonepicardial sites. Heart Rhythm. 2011;8:1525–9.PubMed

114.

Jauregui Abularach ME, Campos B, Park KM, et al. Ablation of ventricular arrhythmias arising near the anterior epicardial veins from the left sinus of Valsalva region: ECG features, anatomic distance, and outcome. Heart Rhythm. 2012;9:865–73.PubMed

115.

Yokokawa M, Good E, Chugh A, et al. Intramural idiopathic ventricular arrhythmias originating in the intraventricular septum: mapping and ablation. Circ Arrhythm Electrophysiol. 2012;5:258–63.PubMed

116.

Doppalapudi H, Yamada T, Ramaswamy K, Ahn J, Kay GN. Idiopathic focal epicardial ventricular tachycardia originating from the crux of the heart. Heart Rhythm. 2009;6:44–50.PubMed

117.

Kawamura M, Gerstenfeld EP, Vedantham V, et al. Idiopathic ventricular arrhythmia originating from the cardiac crux or inferior septum. Circ Arrhythm Electrophysiol. 2014;7:1152–8.PubMed

118.

Larroussi L, Badhwar N. Ventricular tachycardia arising from cardiac crux: electrocardiogram recognition and site of ablation. Card Electrophysiol Clin. 2016;8:109–13.PubMed

119.

Yui Y, Sekiguchi Y, Nogami A, et al. Electrophysiological characteristics and radiofrequency catheter ablation treatment of idiopathic ventricular arrhythmias successfully ablated from the ostium of the coronary sinus. Circ J. 2017;81:1807–15.PubMed

120.

Komatsu Y, Otomo K, Taniguchi H, et al. Catheter ablation of ventricular arrhythmias arising from the right ventricular septum close to the His bundle: features of the local electrogram at the optimal ablation site. J Cardiovasc Electrophysiol. 2011;22:878–85.PubMed

121.

Yamada T, Plumb VJ, McElderry HT, Doppalapudi H, Epstein AE, Kay GN. Focal ventricular arrhythmias originating from the left ventricle adjacent to the membranous septum. Europace. 2010;12:1467–74.PubMed

122.

Wei HQ, Guo XG, Liu X, et al. Safety and efficacy of catheter ablation of ventricular arrhythmias with para-Hisian origin via a systematic direct approach from the aortic sinus cusp. Heart Rhythm. 2018;15:1626–33.PubMed

123.

Yamauchi Y, Aonuma K, Takahashi A, et al. Electrocardiographic characteristics of repetitive monomorphic right ventricular tachycardia originating near the His-bundle. J Cardiovasc Electrophysiol. 2005;16:1041–8.PubMed

124.

Komatsu Y, Taniguchi H, Miyazaki S, et al. Two distinct electrocardiographic forms of idiopathic ventricular arrhythmia originating in the vicinity of the His bundle. Europace. 2012;14:1778–85.PubMed

125.

Enriquez A, Tapias C, Rodriguez D, et al. How to map and ablate parahisian ventricular arrhythmias. Heart Rhythm. 2018;15:1268–74.PubMed

126.

Santangeli P, Hutchinson MD, Supple GE, Callans DJ, Marchlinski FE, Garcia FC. Right atrial approach for ablation of ventricular arrhythmias arising from the left posterior-superior process of the left ventricle. Circ Arrhythm Electrophysiol. 2016;9:e004048.PubMed

127.

Li A, Zuberi Z, Bradfield JS, et al. Endocardial ablation of ventricular ectopic beats arising from the basal inferoseptal process of the left ventricle. Heart Rhythm. 2018;15:1356–62.PubMed

128.

Tavares L, Dave A, Valderrábano M. Successful ablation of premature ventricular contractions originating from the inferoseptal process of the left ventricle using a coronary sinus approach. HeartRhythm Case Rep. 2018;4:371–4.PubMedPubMedCentral

129.

Latchamsetty RY, Morady M, Kim F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clinical Electrophysiol. 2015;1:116–23.

130.

Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med. 1995;333:77–82.PubMed

131.

Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm. 2011;8:1608–14.PubMed

132.

Zang M, Zhang T, Mao J, Zhou S, He B. Beneficial effects of catheter ablation of frequent premature ventricular complexes on left ventricular function. Heart. 2014;100:787–93.PubMed

133.

Lee A, Denman R, Haqqani HM. Ventricular ectopy in the context of left ventricular systolic dysfunction: risk factors and outcomes following catheter ablation. Heart Lung Circ. 2019;28:379–88.PubMed

134.

Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol. 2005;45:1259–65.PubMed

135.

Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865–9.PubMed

136.

Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation. 2005;112:1092–7.PubMed

137.

Wijnmaalen AP, Delgado V, Schalij MJ, et al. Beneficial effects of catheter ablation on left ventricular and right ventricular function in patients with frequent premature ventricular contractions and preserved ejection fraction. Heart. 2010;96:1275–80.PubMed

138.

Sarrazin JF, Labounty T, Kuhne M, et al. Impact of radiofrequency ablation of frequent post-infarction premature ventricular complexes on left ventricular ejection fraction. Heart Rhythm. 2009;6:1543–9.PubMedPubMedCentral

139.

El Kadri M, Yokokawa M, Labounty T, et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. Heart Rhythm. 2015;12:706–13.PubMed

140.

Haïssaguerre M, Shoda M, Jaïs P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106:962–7.PubMed

141.

Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol. 2009;54:522–8.PubMed

142.

Peichl P, Cihák R, Kozeluhová M, Wichterle D, Vancura V, Kautzner J. Catheter ablation of arrhythmic storm triggered by monomorphic ectopic beats in patients with coronary artery disease. J Interv Card Electrophysiol. 2010;27:51–9.PubMed

143.

Haïssaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003;108:925–8.PubMed

144.

Lakkireddy D, Di Biase L, Ryschon K, et al. Radiofrequency ablation of premature ventricular ectopy improves the efficacy of cardiac resynchronization therapy in nonresponders. J Am Coll Cardiol. 2012;60:1531–9.PubMed

145.

Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111–21.PubMed

146.

Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773–82.PubMed

147.

Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. 2010;21:47–53.PubMed

148.

Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016;67:674–83.PubMed

149.

Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation. 2008;117:462–9.PubMed

150.

Deneke T, Shin D, Lawo T, et al. Catheter ablation of electrical storm in a collaborative hospital network. Am J Cardiol. 2011;108:233–9.PubMed

151.

Muser D, Liang JJ, Pathak RK, et al. Long-term outcomes of catheter ablation of electrical storm in nonischemic dilated cardiomyopathy compared with ischemic cardiomyopathy. JACC Clin Electrophysiol. 2017;3:767–78.PubMed

152.

Kumar S, Fujii A, Kapur S, et al. Beyond the storm: comparison of clinical factors, arrhythmogenic substrate, and catheter ablation outcomes in structural heart disease patients with versus those without a history of ventricular tachycardia storm. J Cardiovasc Electrophysiol. 2017;28:56–67.PubMed

153.

Nayyar S, Ganesan AN, Brooks AG, Sullivan T, Roberts-Thomson KC, Sanders P. Venturing into ventricular arrhythmia storm: a systematic review and meta-analysis. Eur Heart J. 2013;34:560–9.PubMed

154.

Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657–65.PubMedPubMedCentral

155.

Kuck KH, Schaumann A, Eckhardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31–40.PubMed

156.

Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol. 2015;26:151–7.PubMed

157.

Kuck KH, Tilz RR, Deneke T, et al. Impact of substrate modification by catheter ablation on implantable cardioverter–defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol. 2017;10:e004422.PubMed

158.

Littmann L, Svenson RH, Gallagher JJ, et al. Functional role of the epicardium in postinfarction ventricular tachycardia: observations derived from computerized epicardial activation mapping, entrainment, and epicardial laser photoablation. Circulation. 1991;83:1577–91.PubMed

159.

Sosa E, Scanavacca M, d’Avila A, Oliveira F, Ramires JA. Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction. J Am Coll Cardiol. 2000;35:1442–9.PubMed

160.

Schmidt B, Chun KR, Baensch D, Antz M, Koektuerk B, Tilz RR, et al. Catheter ablation for ventricular tachycardia after failed endocardial ablation: epicardial substrate or inappropriate endocardial ablation? Heart Rhythm. 2010;7:1746–52.PubMed

161.

Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited endocardial substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2012;60:132–41.PubMed

162.

Izquierdo M, Sánchez-Gómez JM, Ferrero de Loma-Osorio A, Martínez A, Bellver A, Peláez A, et al. Endo-epicardial versus only-endocardial ablation as a first line strategy for the treatment of ventricular tachycardia in patients with ischemic heart disease. Circ Arrhythm Electrophysiol. 2015;8:882–9.PubMed

163.

Muser D, Santangeli P, Castro SA, et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9:e004328.PubMed

164.

Proietti R, Essebag V, Beardsall J, et al. Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace. 2015;17:461–7.PubMed

165.

Dinov B, Arya A, Bertagnolli L, et al. Early referral for ablation of scar-related ventricular tachycardia is associated with improved acute and long-term outcomes: results from the Heart Center of Leipzig ventricular tachycardia registry. Circ Arrhythm Electrophysiol. 2014;7:1144–51.PubMed

166.

Dinov B, Fiedler L, Schönbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) study. Circulation. 2014;129:728–36.PubMed

167.

Tokuda M, Tedrow UB, Kojodjojo P, et al. Catheter ablation of ventricular tachycardia in nonischemic heart disease. Circ Arrhythm Electrophysiol. 2012;5:992–1000.PubMed

168.

Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12:1997–2007.PubMedPubMedCentral

169.

Arya A, Bode K, Piorkowski C, et al. Catheter ablation of electrical storm due to monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy: acute results and its effect on long-term survival. Pacing Clin Electrophysiol. 2010;33:1504–9.PubMed

170.

Hu J, Zeng S, Zhou Q, et al. Can ventricular tachycardia non-inducibility after ablation predict reduced ventricular tachycardia recurrence and mortality in patients with non-ischemic cardiomyopathy? A meta-analysis of twenty-four observational studies. Int J Cardiol. 2016;222:689–95.PubMed

171.

Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol. 2011;4:653–9.PubMed

172.

Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol. 2010;55:2366–72.PubMed

173.

Cano O, Hutchinson M, Lin D, et al. Electroanatomic substrate and ablation outcome for suspected epicardial ventricular tachycardia in left ventricular nonischemic cardiomyopathy. J Am Coll Cardiol. 2009;54:799–808.PubMed

174.

Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm. 2009;6:189–95.PubMed

175.

Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407–13.PubMed

176.

Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol. 2015;8:87–93.PubMed

177.

Muser D, Santangeli P, Pathak RK, et al. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2016;9:e004333.PubMed

178.

Papageorgiou N, Providência R, Bronis K, et al. Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. Europace. 2018;20:682–91.PubMed

179.

Kumar S, Androulakis AF, Sellal JM, et al. Multicenter experience with catheter ablation for ventricular tachycardia in lamin A/C cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9:e004357.PubMed

180.

Cohen TJ, Chien WW, Lurie KG, et al. Radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia: results and long-term follow-up. J Am Coll Cardiol. 1991;18:1767–73.PubMed

181.

Blank Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M. Bundle branch reentrant ventricular tachycardia: Cumulative experience in 48 patients. J Cardiovasc Electrophysiol. 1993;4:253–62.

182.

Mehdirad AA, Keim S, Rist K, Tchou P. Long-term clinical outcome of right bundle branch radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia. Pacing Clin Electrophysiol. 1995;18(12 Pt 1):2135–43.PubMed

183.

Pathak RK, Fahed J, Santangeli P, et al. Long-term outcome of catheter ablation for treatment of bundle branch re-entrant tachycardia. JACC Clin Electrophysiol. 2018;4:331–8.PubMed

184.

Narasimhan C, Jazayeri MR, Sra J, et al. Ventricular tachycardia in valvular heart disease: facilitation of bundle-branch reentry by valve surgery. Circulation. 1997;96:4307–13.PubMed

185.

Li YG, Grönefeld G, Israel C, Bogun F, Hohnloser SH. Bundle branch reentrant tachycardia in patients with apparent normal His-Purkinje conduction: the role of functional conduction impairment. J Cardiovasc Electrophysiol. 2002;13:1233–9.PubMed

186.

Schmidt B, Tang M, Chun KR, et al. Left bundle branch-Purkinje system in patients with bundle branch reentrant tachycardia: lessons from catheter ablation and electroanatomic mapping. Heart Rhythm. 2009;6:51–8.PubMed

187.

Blanck Z, Jazayeri M, Dhala A, Deshpande S, Sra J, Akhtar M. Bundle branch reentry: a mechanism of ventricular tachycardia in the absence of myocardial or valvular dysfunction. J Am Coll Cardiol. 1993;22:1718–22.PubMed

188.

Chen H, Shi L, Yang B, et al. Electrophysiological characteristics of bundle branch reentry ventricular tachycardia in patients without structural heart disease. Circ Arrhythm Electrophysiol. 2018;11:e006049.PubMed

189.

Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2000;36:811–23.PubMed

190.

Ouyang F, Cappato R, Ernst S, et al. Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the Purkinje network. Circulation. 2002;105:462–9.PubMed

191.

Liu Y, Fang Z, Yang B, et al. Catheter ablation of fascicular ventricular tachycardia: long-term clinical outcomes and mechanisms of recurrence. Circ Arrhythm Electrophysiol. 2015;8:1443–51.PubMedPubMedCentral

192.

Nakagawa H, Beckman KJ, McClelland JH, et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation. 1993;88:2607–17.PubMed

193.

Chen M, Yang B, Zou J, et al. Non-contact mapping and linear ablation of the left posterior fascicle during sinus rhythm in the treatment of idiopathic left ventricular tachycardia. Europace. 2005;7:138–44.PubMed

194.

Kottkamp H, Chen X, Hindricks G, et al. Idiopathic left ventricular tachycardia: new insights into electrophysiological characteristics and radiofrequency catheter ablation. Pacing Clin Electrophysiol. 1995;18:1285–97.PubMed

195.

Lin D, Hsia HH, Gerstenfeld EP, et al. Idiopathic fascicular left ventricular tachycardia: linear ablation lesion strategy for noninducible or nonsustained tachycardia. Heart Rhythm. 2005;2:934–9.PubMed

196.

Tada H, Nogami A, Naito S, et al. Retrograde Purkinje potential activation during sinus rhythm following catheter ablation of idiopathic left ventricular tachycardia. J Cardiovasc Electrophysiol. 1998;9:1218–24.PubMed

197.

Tsuchiya T, Okumura K, Honda T, et al. Significance of late diastolic potential preceding Purkinje potential in verapamil-sensitive idiopathic left ventricular tachycardia. Circulation. 1999;99:2408–13.PubMed

198.

Wen MS, Yeh SJ, Wang CC, Lin FC, Wu D. Successful radiofrequency ablation of idiopathic left ventricular tachycardia at a site away from the tachycardia exit. J Am Coll Cardiol. 1997;30:1024–31.PubMed

199.

Arya A, Haghjoo M, Emkanjoo Z, et al. Comparison of presystolic Purkinje and late diastolic potentials for selection of ablation site in idiopathic verapamil sensitive left ventricular tachycardia. J Interv Card Electrophysiol. 2004;11:135–41.PubMed

200.

Liu Q, Shehata M, Jiang R, et al. Macroreentrant loop in ventricular tachycardia from the left posterior fascicle: new implications for mapping and ablation. Circ Arrhythm Electrophysiol. 2016;9:e004272.PubMed

201.

Guo XG, Liu X, Zhou GB, et al. Clinical, electrocardiographic, and electrophysiological characteristics of left upper septal fascicular ventricular tachycardia. Europace. 2018;20:673–81.PubMed

202.

Collins KK, Schaffer MS, Liberman L, et al. Fascicular and nonfascicular left ventricular tachycardias in the young: an international multicenter study. J Cardiovasc Electrophysiol. 2013;24:640–8.PubMed

203.

Suzuki T, Nakamura Y, Yoshida S, et al. Radiofrequency catheter ablation of idiopathic left anterior fascicular ventricular tachycardia in children. Heart Rhythm. 2014;11:1948–56.PubMed

204.

Fishberger SB, Olen MM, Rollinson NL, Rossi AF. Creation of partial fascicular block: an approach to ablation of idiopathic left ventricular tachycardia in the pediatric population. Pacing Clin Electrophysiol. 2015;38:209–15.PubMed

205.

Saul JP, Kanter RJ, Abrams D, et al. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the Association for European Pediatric and Congenital Cardiology (AEPC). Heart Rhythm. 2016;13:e251–89.

206.

Talib AK, Nogami A, Morishima I, et al. Non-reentrant fascicular tachycardia: clinical and electrophysiological characteristics of a distinct type of idiopathic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2016;9:e004177.PubMed

207.

Lopera G, Stevenson WG, Soejima K, et al. Identification and ablation of three types of ventricular tachycardia involving the His-Purkinje system in patients with heart disease. J Cardiovasc Electrophysiol. 2004;15:52–8.PubMed

208.

Gonzalez RP, Scheinman MM, Lesh MD, Helmy I, Torres V, Van Hare GF. Clinical and electrophysiologic spectrum of fascicular tachycardias. Am Heart J. 1994;128:147–56.PubMed

209.

Nogami A. Purkinje-related arrhythmias. Part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol. 2011;34:624–50.PubMed

210.

Hayashi M, Kobayashi Y, Iwasaki YK, et al. Novel mechanism of postinfarction ventricular tachycardia originating in surviving left posterior Purkinje fibers. Heart Rhythm. 2006;3:908–18.PubMed

211.

Bogun F, Good E, Reich S, et al. Role of Purkinje fibers in post-infarction ventricular tachycardia. J Am Coll Cardiol. 2006;48:2500–7.PubMed

212.

Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231–7.PubMed

213.

Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. 1997;30:1368–73.PubMed

214.

Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart. 2008;94:211–6.PubMed

215.

Diller GP, Kempny A, Liodakis E, et al. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of Fallot. Circulation. 2012;125:2440–6.PubMed

216.

Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;126:1944–54.PubMed

217.

Koyak Z, de Groot JR, Bouma BJ, et al. Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen? Europace. 2017;19:401–6.PubMed

218.

Deal BJ, Scagliotti D, Miller SM, Gallastegui JL, Hariman RJ, Levitsky S. Electrophysiologic drug testing in symptomatic ventricular arrhythmias after repair of tetralogy of Fallot. Am J Cardiol. 1987;59:1380–5.PubMed

219.

Oechslin EN, Harrison DA, Harris L, et al. Reoperation in adults with repair of tetralogy of Fallot: indications and outcomes. J Thorac Cardiovasc Surg. 1999;118:245–51.PubMed

220.

Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation. 2001;103:2489–94.PubMed

221.

Therrien J, Provost Y, Merchant N, Williams W, Colman J, Webb G. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;95:779–82.PubMed

222.

Mavroudis C, Deal BJ, Backer CL, Tsao S. Arrhythmia surgery in patients with and without congenital heart disease. Ann Thorac Surg. 2008;86:857–68.PubMed

223.

Adamson L, Vohra HA, Haw MP. Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interact Cardiovasc Thorac Surg. 2009;9:520–7.PubMed

224.

Miyazaki A, Sakaguchi H, Ohuchi H, et al. Efficacy of hemodynamic-based management of tachyarrhythmia after repair of tetralogy of Fallot. Circ J. 2012;76:2855–62.PubMed

225.

Lin YS, Liu PH, Wu LS, Chen YM, Chang CJ, Chu PH. Major adverse cardiovascular events in adult congenital heart disease: a population-based follow-up study from Taiwan. BMC Cardiovasc Disord. 2014;14:38.PubMedPubMedCentral

226.

Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol. 2015;8:110–6.PubMed

227.

Gonska BD, Cao K, Raab J, Eigster G, Kreuzer H. Radiofrequency catheter ablation of right ventricular tachycardia late after repair of congenital heart defects. Circulation. 1996;94:1902–8.PubMed

228.

Morwood JG, Triedman JK, Berul CI, et al. Radiofrequency catheter ablation of ventricular tachycardia in children and young adults with congenital heart disease. Heart Rhythm. 2004;1:301–8.PubMed

229.

Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation. 2007;116:2241–52.PubMed

230.

Kriebel T, Saul JP, Schneider H, Sigler M, Paul T. Noncontact mapping and radiofrequency catheter ablation of fast and hemodynamically unstable ventricular tachycardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol. 2007;50:2162–8.PubMed

231.

Kapel GF, Reichlin T, Wijnmaalen AP, et al. Left-sided ablation of ventricular tachycardia in adults with repaired tetralogy of Fallot: a case series. Circ Arrhythm Electrophysiol. 2014;7:889–97.PubMed

232.

Kapel GF, Reichlin T, Wijnmaalen AP, et al. Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ Arrhythm Electrophysiol. 2015;8:102–9.PubMed

233.

van Zyl M, Kapa S, Padmanabhan D, et al. Mechanism and outcomes of catheter ablation for ventricular tachycardia in adults with repaired congenital heart disease. Heart Rhythm. 2016;13:1449–54.PubMed

234.

Kapel GF, Sacher F, Dekkers OM, et al. Arrhythmogenic anatomical isthmuses identified by electroanatomical mapping are the substrate for ventricular tachycardia in repaired tetralogy of Fallot. Eur Heart J. 2017;38:268–76.PubMed

235.

Sandhu A, Ruckdeschel E, Sauer WH, et al. Perioperative electrophysiology study in patients with tetralogy of Fallot undergoing pulmonary valve replacement will identify those at high risk of subsequent ventricular tachycardia. Heart Rhythm. 2018;15:679–85.PubMed

236.

Berruezo A, Acosta J, Fernández-Armenta J, et al. Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study. Europace. 2017;19:607–16.PubMed

237.

Jiang H, Zhang X, Yang Q, et al. Catheter ablation for ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: a systematic review and meta-analysis. Acta Cardiol. 2016;71:639–49.PubMed

238.

Philips B, te Riele AS, Sawant A, et al. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2015;12:716–25.PubMed

239.

Santangeli P, Zado ES, Supple GE, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8:1413–21.PubMed

240.

Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012;5:499–505.PubMed

241.

Bai R, Di Biase L, Shivkumar K, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol. 2011;4:478–85.PubMed

242.

Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2009;120:366–75.PubMed

243.

Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50:432–40.PubMed

244.

Verma A, Kilicaslan F, Schweikert RA, et al. Short- and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia. Circulation. 2005;111:3209–16.PubMed

245.

Marchlinski FE, Zado E, Dixit S, et al. Electroanatomic substrate and outcome of catheter ablative therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy. Circulation. 2004;110:2293–8.PubMed

246.

Nogami A, Sugiyasu A, Tada H, et al. Changes in the isolated delayed component as an endpoint of catheter ablation in arrhythmogenic right ventricular cardiomyopathy: predictor for long-term success. J Cardiovasc Electrophysiol. 2008;19:681–8.PubMed

247.

Müssigbrodt A, Efimova E, Knopp H, et al. Should all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergo epicardial catheter ablation? J Interv Card Electrophysiol. 2017;48:193–9.PubMed

248.

Pokushalov E, Romanov A, Turov A, Artyomenko S, Shirokova N, Karaskov A. Percutaneous epicardial ablation of ventricular tachycardia after failure of endocardial approach in the pediatric population with arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2010;7:1406–10.PubMed

249.

Pappone C, Brugada J, Vicedomini G, et al. Electrical substrate elimination in 135 consecutive patients with Brugada syndrome. Circ Arrhythm Electrophysiol. 2017;10:e005053.PubMed

250.

Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol. 2015;8:1373–81.PubMed

251.

Zhang P, Tung R, Zhang Z, et al. Characterization of the epicardial substrate for catheter ablation of Brugada syndrome. Heart Rhythm. 2016;13:2151–8.PubMed

252.

Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011;123:1270–9.PubMed

253.

Berruezo A, Fernández-Armenta J, Mont L, et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol. 2012;5:111–21.PubMed

254.

Dukkipati SR, d’Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4:185–94.PubMed

255.

Santangeli P, Di Biase L, Lakkireddy D, et al. Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility. Heart Rhythm. 2010;7:1036–42.PubMed

256.

Ueda A, Fukamizu S, Soejima K, et al. Clinical and electrophysiological characteristics in patients with sustained monomorphic reentrant ventricular tachycardia associated with dilated-phase hypertrophic cardiomyopathy. Europace. 2012;14:734–40.PubMed

257.

Inada K, Seiler J, Roberts-Thomson KC, et al. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011;22:41–8.PubMed

258.

Igarashi M, Nogami A, Kurosaki K, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm. JACC Clin Electrophysiol. 2018;4:339–50.PubMed

259.

Visser CA, Kan G, David GK, Lie KI, Durrer D. Two dimensional echocardiography in the diagnosis of left ventricular thrombus: a prospective study of 67 patients with anatomic validation. Chest. 1983;83:228–32.PubMed

260.

Ezekowitz MD, Wilson DA, Smith EO, et al. Comparison of Indium-111 platelet scintigraphy and two-dimensional echocardiography in the diagnosis of left ventricular thrombi. N Engl J Med. 1982;306:1509–13.PubMed

261.

Stratton JR, Lighty GW Jr, Pearlman AS, Ritchie JL. Detection of left ventricular thrombus by two-dimensional echocardiography: sensitivity, specificity, and causes of uncertainty. Circulation. 1982;66:156–66.PubMed

262.

Thanigaraj S, Schechtman KB, Perez JE. Improved echocardiographic delineation of left ventricular thrombus with the use of intravenous second-generation contrast image enhancement. J Am Soc Echocardiogr. 1999;12:1022–6.PubMed

263.

Weinsaft JW, Kim HW, Shah DJ, et al. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol. 2008;52:148–57.PubMed

264.

Weinsaft JW, Kim RJ, Ross M, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging. 2009;2:969–79.PubMedPubMedCentral

265.

Siontis KC, Kim HM, Sharaf Dabbagh G, et al. Association of preprocedural cardiac magnetic resonance imaging with outcomes of ventricular tachycardia ablation in patients with idiopathic dilated cardiomyopathy. Heart Rhythm. 2017;14:1487–93.PubMed

266.

Zghaib T, Ipek EG, Hansford R, et al. Standard ablation versus magnetic resonance imaging-guided ablation in the treatment of ventricular tachycardia. Circ Arrhythm Electrophysiol. 2018;11:e005973.PubMedPubMedCentral

267.

Andreu D, Penela D, Acosta J, et al. Cardiac magnetic resonance-aided scar dechanneling: Influence on acute and long-term outcomes. Heart Rhythm. 2017;14:1121–8.PubMed

268.

Codreanu A, Odille F, Aliot E, et al. Electroanatomic characterization of post-infarct scars comparison with 3-dimensional myocardial scar reconstruction based on magnetic resonance imaging. J Am Coll Cardiol. 2008;52:839–42.PubMed

269.

Desjardins B, Crawford T, Good E, et al. Infarct architecture and characteristics on delayed enhanced magnetic resonance imaging and electroanatomic mapping in patients with postinfarction ventricular arrhythmia. Heart Rhythm. 2009;6:644–51.PubMedPubMedCentral

270.

Bogun FM, Desjardins B, Good E, et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53:1138–45.PubMedPubMedCentral

271.

Dickfeld T, Tian J, Ahmad G, et al. MRI-guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol. 2011;4:172–84.PubMed

272.

Fernandez-Armenta J, Berruezo A, Andreu D, et al. Three-dimensional architecture of scar and conducting channels based on high resolution ce-CMR: insights for ventricular tachycardia ablation. Circ Arrhythm Electrophysiol. 2013;6:528–37.PubMed

273.

Gupta S, Desjardins B, Baman T, et al. Delayed-enhanced MR scar imaging and intraprocedural registration into an electroanatomical mapping system in post-infarction patients. JACC Cardiovasc Imaging. 2012;5:207–10.PubMedPubMedCentral

274.

Marra MP, Leoni L, Bauce B, et al. Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy: comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol. 2012;5:91–100.PubMed

275.

Nakahara S, Vaseghi M, Ramirez RJ, et al. Characterization of myocardial scars: electrophysiological imaging correlates in a porcine infarct model. Heart Rhythm. 2011;8:1060–7.PubMed

276.

Ghannam M, Cochet H, Jais P, et al. Correlation between computer tomography-derived scar topography and critical ablation sites in postinfarction ventricular tachycardia. J Cardiovasc Electrophysiol. 2018;29:438–45.PubMed

277.

Esposito A, Palmisano A, Antunes S, et al. Cardiac CT with delayed enhancement in the characterization of ventricular tachycardia structural substrate: relationship between CT-segmented scar and electro-anatomic mapping. JACC Cardiovasc Imaging. 2016;9:822–32.PubMed

278.

Tian J, Jeudy J, Smith MF, et al. Three-dimensional contrast-enhanced multidetector CT for anatomic, dynamic, and perfusion characterization of abnormal myocardium to guide ventricular tachycardia ablations. Circ Arrhythm Electrophysiol. 2010;3:496–504.PubMed

279.

Yamashita S, Sacher F, Mahida S, et al. Image integration to guide catheter ablation in scar-related ventricular tachycardia. J Cardiovasc Electrophysiol. 2016;27:699–708.PubMed

280.

Komatsu Y, Cochet H, Jadidi A, et al. Regional myocardial wall thinning at multidetector computed tomography correlates to arrhythmogenic substrate in postinfarction ventricular tachycardia: assessment of structural and electrical substrate. Circ Arrhythm Electrophysiol. 2013;6:342–50.PubMed

281.

Dickfeld T, Lei P, Dilsizian V, et al. Integration of three-dimensional scar maps for ventricular tachycardia ablation with positron emission tomography-computed tomography. JACC Cardiovasc Imaging. 2008;1:73–82.PubMed

282.

Tian J, Smith MF, Chinnadurai P, et al. Clinical application of PET/CT fusion imaging for three-dimensional myocardial scar and left ventricular anatomy during ventricular tachycardia ablation. J Cardiovasc Electrophysiol. 2009;20:567–604.PubMed

283.

Andreu D, Ortiz-Perez JT, Boussy T, et al. Usefulness of contrast-enhanced cardiac magnetic resonance in identifying the ventricular arrhythmia substrate and the approach needed for ablation. Eur Heart J. 2014;35:1316–26.PubMed

284.

Soto-Iglesias D, Acosta J, Penela D, et al. Image-based criteria to identify the presence of epicardial arrhythmogenic substrate in patients with transmural myocardial infarction. Heart Rhythm. 2018;15:814–21.PubMed

285.

Wutzler A, Mueller A, Loehr L, et al. Minimal and deep sedation during ablation of ventricular tachycardia. Int J Cardiol. 2014;172:161–4.PubMed

286.

Servatius H, Höfeler T, Hoffmann BA, et al. Propofol sedation administered by cardiologists for patients undergoing catheter ablation for ventricular tachycardia. Europace. 2016;18:1245–51.PubMed

287.

Nazer B, Woods C, Dewland T, Moyers B, Badhwar N, Gerstenfeld EP. Importance of ventricular tachycardia induction and mapping for patients referred for epicardial ablation. Pacing Clin Electrophysiol. 2015;38:1333–42.PubMed

288.

Sharma PS, Padala SK, Gunda S, Koneru JN, Ellenbogen KA. Vascular complications during catheter ablation of cardiac arrhythmias: a comparison between vascular ultrasound guided access and conventional vascular access. J Cardiovasc Electrophysiol. 2016;27:1160–6.PubMed

289.

Tanaka-Esposito CC, Chung MK, Abraham JM, Cantillon DJ, Abi-Saleh B, Tchou PJ. Real-time ultrasound guidance reduces total and major vascular complications in patients undergoing pulmonary vein antral isolation on therapeutic warfarin. J Interv Card Electrophysiol. 2013;37:163–8.PubMedPubMedCentral

290.

Yamagata K, Wichterle D, Roubíček T, et al. Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-FAST trial). Europace. 2018;20:1107–14.PubMed

291.

Sobolev M, Shiloh AL, Di Biase L, Slovut DP. Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis. Europace. 2017;19:850–5.PubMed

292.

Seto AH, Abu-Fadel MS, Sparling JM, et al. Real-time ultrasound guidance facilitates femoral arterial access and reduces vascular complications: FAUST (Femoral Arterial Access With Ultrasound Trial). JACC Cardiovasc Interv. 2010;3:751–8.PubMed

293.

Miller MA, Dukkipati SR, Mittnacht AJ, et al. Activation and entrainment mapping of hemodynamically unstable ventricular tachycardia using a percutaneous left ventricular assist device. J Am Coll Cardiol. 2011;58:1363–71.PubMed

294.

Reddy YM, Chinitz L, Mansour M, et al. Percutaneous left ventricular assist devices in ventricular tachycardia ablation: multicenter experience. Circ Arrhythm Electrophysiol. 2014;7:244–50.PubMedPubMedCentral

295.

Baratto F, Pappalardo F, Oloriz T, et al. Extracorporeal membrane oxygenation for hemodynamic support of ventricular tachycardia ablation. Circ Arrhythm Electrophysiol. 2016;9:e004492.PubMed

296.

Kusa S, Miller MA, Whang W, et al. Outcomes of ventricular tachycardia ablation using percutaneous left ventricular assist devices. Circ Arrhythm Electrophysiol. 2017;10:e004717.PubMed

297.

Mathuria N, Wu G, Rojas-Delgado F, et al. Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol. 2017;48:27–34.PubMed

298.

Turagam MK, Vuddanda V, Atkins D, et al. Hemodynamic support in ventricular tachycardia ablation: an International VT Ablation Center Collaborative Group Study. JACC Clin Electrophysiol. 2017;3:1534–43.PubMed

299.

Enriquez A, Liang J, Gentile J, et al. Outcomes of rescue cardiopulmonary support for periprocedural acute hemodynamic decompensation in patients undergoing catheter ablation of electrical storm. Heart Rhythm. 2018;15:75–80.PubMed

300.

Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol. 2000;35:1905–14.PubMed

301.

Siontis KC, Jamé S, Sharaf Dabbagh G, et al. Thromboembolic prophylaxis protocol with warfarin after radiofrequency catheter ablation of infarct-related ventricular tachycardia. J Cardiovasc Electrophysiol. 2018;29:584–90.PubMed

302.

Di Biase L, Burkhardt JD, Lakkireddy D, et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy: the VISTA randomized multicenter trial. J Am Coll Cardiol. 2015;66:2872–82.PubMed

303.

Volkmer M, Ouyang F, Deger F, et al. Substrate mapping vs. tachycardia mapping using CARTO in patients with coronary artery disease and ventricular tachycardia: impact on outcome of catheter ablation. Europace. 2006;8:968–76.PubMed

304.

Makimoto H, Nakajima I, Miyamoto K, et al. Clinical impact of mapping strategies for treatment of ventricular tachycardias in patients with structural heart disease. Pacing Clin Electrophysiol. 2015;38:630–40.PubMed

305.

Carbucicchio C, Ahmad Raja N, Di Biase L, et al. High-density substrate-guided ventricular tachycardia ablation: role of activation mapping in an attempt to improve procedural effectiveness. Heart Rhythm. 2013;10:1850–8.PubMed

306.

Briceño DF, Romero J, Villablanca PA, et al. Long-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease: systematic review and meta-analysis. Europace. 2018;20:104–15.PubMed

307.

Kumar S, Baldinger SH, Romero J, et al. Substrate-based ablation versus ablation guided by activation and entrainment mapping for ventricular tachycardia: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2016;27:1437–47.PubMed

308.

Acosta J, Penela D. Andreu D, et al. Multielectrode vs. point-by-point mapping for ventricular tachycardia substrate ablation: a randomized study. Europace. 2018;20:512–9.PubMed

309.

Berte B, Relan J, Sacher F, et al. Impact of electrode type on mapping of scar-related VT. J Cardiovasc Electrophysiol. 2015;26:1213–23.PubMed

310.

Yamashita S, Cochet H, Sacher F, et al. Impact of new technologies and approaches for post-myocardial infarction ventricular tachycardia ablation during long-term follow-up. Circ Arrhythm Electrophysiol. 2016;9:e003901.PubMed

311.

Hutchinson MD, Gerstenfeld EP, Desjardins B, et al. Endocardial unipolar voltage mapping to detect epicardial ventricular tachycardia substrate in patients with nonischemic left ventricular cardiomyopathy. Circ Arrhythmia Electrophysiol. 2011;4:49–55.

312.

Polin GM, Haqqani H, Tzou W, et al. Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2011;8:76–83.PubMed

313.

Chopra N, Tokuda M, Ng J, et al. Relation of the unipolar low-voltage penumbra surrounding the endocardial low-voltage scar to ventricular tachycardia circuit sites and ablation outcomes in ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2014;25:602–8.PubMed

314.

Soto-Becerra R, Bazan V, Bautista W, et al. Ventricular tachycardia in the setting of Chagasic cardiomyopathy. Circ Arrhythm Electrophysiol. 2017;10:e004950.PubMed

315.

Hoffmayer KS, Dewland TA, Hsia HH, et al. Safety of radiofrequency catheter ablation without coronary angiography in aortic cusp ventricular arrhythmias. Heart Rhythm. 2014;11:1117–21.PubMed

316.

Hachiya H, Aonuma K, Yamauchi Y, Igawa M, Nogami A, Iesaka Y. How to diagnose, locate, and ablate coronary cusp ventricular tachycardia. J Cardiovasc Electrophysiol. 2002;13:551–6.PubMed

317.

Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coll Cardiol. 2008;52:139–47.PubMed

318.

D’Avila A, Gutierrez P, Scanavacca M, et al. Effects of radiofrequency pulses delivered in the vicinity of the coronary arteries: implications for nonsurgical transthoracic epicardial catheter ablation to treat ventricular tachycardia. Pacing Clin Electrophysiol. 2002;25:1488–95.PubMed

319.

Good E, Desjardins B, Jongnarangsin K, et al. Ventricular arrhythmias originating from a papillary muscle in patients without prior infarction: a comparison with fascicular arrhythmias. Heart Rhythm. 2008;5:1530–7.PubMed

320.

Proietti R, Rivera S, Dussault C, et al. Intracardiac echo-facilitated 3D electroanatomical mapping of ventricular arrhythmias from the papillary muscles: assessing the ‘fourth dimension’ during ablation. Europace. 2017;19:21–8.PubMed

321.

Peichl P, Baran J, Wichterle D, et al. The tip of the muscle is a dominant location of ventricular ectopy originating from papillary muscles in the left ventricle. J Cardiovasc Electrophysiol. 2018;29:64–70.PubMed

322.

Lee A, Hamilton-Craig C, Denman R, Haqqani HM. Catheter ablation of papillary muscle arrhythmias: implications of mitral valve prolapse and systolic dysfunction. Pacing Clin Electrophysiol. 2018;41:750–8.PubMed

323.

Ren JF, Marchlinski FE. Early detection of iatrogenic pericardial effusion: importance of intracardiac echocardiography. JACC Cardiovasc Interv. 2010;3:127.PubMed

324.

Filgueiras-Rama D, de Torres-Alba F, Castrejón-Castrejón S, et al. Utility of intracardiac echocardiography for catheter ablation of complex cardiac arrhythmias in a medium-volume training center. Echocardiography. 2015;32:660–70.PubMed

325.

Weintraub AR, Schwartz SL, Smith J, Hsu TL, Pandian NG. Intracardiac two-dimensional echocardiography in patients with pericardial effusion and cardiac tamponade. J Am Soc Echocardiogr. 1991;4:571–6.PubMed

326.

Bala R, Ren JF, Hutchinson MD, et al. Assessing epicardial substrate using intracardiac echocardiography during VT ablation. Circ Arrhythm Electrophysiol. 2011;4:667–73.PubMedPubMedCentral

327.

Peichl P, Wichterle D, Cihak R, Aldhoon B, Kautzner J. Catheter ablation of ventricular tachycardia in the presence of an old endocavitary thrombus guided by intracardiac echocardiography. Pacing Clin Electrophysiol. 2016;39:581–7.PubMed

328.

Khaykin Y, Skanes A, Whaley B, et al. Real-time integration of 2D intracardiac echocardiography and 3D electroanatomical mapping to guide ventricular tachycardia ablation. Heart Rhythm. 2008;5:1396–402.PubMed

329.

Sporton SC, Earley MJ, Nathan AW, Schilling RJ. Electroanatomic versus fluoroscopic mapping for catheter ablation procedures: a prospective randomized study. J Cardiovasc Electrophysiol. 2004;15:310–5.PubMed

330.

Earley MJ, Showkathali R, Alzetani M, et al. Radiofrequency ablation of arrhythmias guided by non-fluoroscopic catheter location: a prospective randomized trial. Eur Heart J. 2006;27:1223–9.PubMed

331.

Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation. 2000;101:1288–96.PubMed

332.

Khongphatthanayothin A, Kosar E, Nademanee K. Nonfluoroscopic three-dimensional mapping for arrhythmia ablation: tool or toy? J Cardiovasc Electrophysiol. 2000;11:239–43.PubMed

333.

Reithmann C, Hahnefeld A, Remp T, et al. Electroanatomic mapping of endocardial right ventricular activation as a guide for catheter ablation in patients with arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol. 2003;26:1308–16.PubMed

334.

Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease. Circulation. 2007;116:2241–52.PubMed

335.

Dinov B, Schoenbauer R, Wojdyla-Horodynska A, et al. Long-term efficacy of single procedure remote magnetic catheter navigation for ablation of ischemic ventricular tachycardia: a retrospective study. J Cardiovasc Electrophysiol. 2012;23:499–505.PubMed

336.

Szili-Torok T, Schwagten B, Akca F, et al. Catheter ablation of ventricular tachycardias using remote magnetic navigation: a consecutive case-control study. J Cardiovasc Electrophysiol. 2012;23:948–54.PubMed

337.

Akca F, Theuns DA, Abkenari LD, de Groot NM, Jordaens L, Szili-Torok T. Outcomes of repeat catheter ablation using magnetic navigation or conventional ablation. Europace. 2013;15:1426–31.PubMed

338.

Bauernfeind T, Akca F, Schwagten B, et al. The magnetic navigation system allows safety and high efficacy for ablation of arrhythmias. Europace. 2011;13:1015–21.PubMedPubMedCentral

339.

Jais P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. 2012;125:2184–96.PubMed

340.

Tilz RR, Makimoto H, Lin T, et al. Electrical isolation of a substrate after myocardial infarction: a novel ablation strategy for unmappable ventricular tachycardias–feasibility and clinical outcome. Europace. 2014;16:1040–52.PubMed

341.

Tzou WS, Frankel DS, Hegeman T, et al. Core isolation of critical arrhythmia elements for treatment of multiple scar-based ventricular tachycardias. Circ Arrhythm Electrophysiol. 2015;8:353–61.PubMed

342.

Silberbauer J, Oloriz T, Maccabelli G, et al. Noninducibility and late potential abolition: a novel combined prognostic procedural end point for catheter ablation of postinfarction ventricular tachycardia. Circ Arrhythm Electrophysiol. 2014;7:424–35.PubMed

343.

Wolf M, Sacher F, Cochet H, et al. Long-term outcome of substrate modification in ablation of post-myocardial infarction ventricular tachycardia. Circ Arrhythm Electrophysiol. 2018;11:e005635.PubMed

344.

Berruezo A, Fernandez-Armenta J, Andreu D, et al. Scar dechanneling: new method for scar-related left ventricular tachycardia substrate ablation. Circ Arrhythm Electrophysiol. 2015;8:326–36.PubMed

345.

Porta-Sanchez A, Jackson N, Lukac P, et al. Multicenter study of ischemic ventricular tachycardia ablation with decrement-evoked potential (DEEP) mapping with extra stimulus. JACC Clin Electrophysiol. 2018;4:307–15.PubMed

346.

de Riva M, Naruse Y, Ebert M, et al. Targeting the hidden substrate unmasked by right ventricular extrastimulation improves ventricular tachycardia ablation outcome after myocardial infarction. JACC Clin Electrophysiol. 2018;4:316–27.PubMed

347.

Koplan BA, Soejima K, Baughman KL, Epstein LM, Stevenson WG. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm. 2006;3:924–9.PubMed

348.

Dechering DG, Kochhaüser S, Wasmer K, et al. Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2013;10:158–64.PubMed

349.

350.

Palaniswamy C, Kolte D, Harikrishnan P, et al. Catheter ablation of postinfarction ventricular tachycardia: ten-year trends in utilization, in-hospital complications, and in-hospital mortality in the United States. Heart Rhythm. 2014;11:2056–63.PubMed

351.

Santangeli P, Muser D, Zado ES, et al. Acute hemodynamic decompensation during catheter ablation of scar-related ventricular tachycardia: incidence, predictors, and impact on mortality. Circ Arrhythm Electrophysiol. 2015;8:68–75.PubMed

352.

Katz DF, Turakhia MP, Sauer WH, et al. Safety of ventricular tachycardia ablation in clinical practice: findings from 9699 hospital discharge records. Circ Arrhythmia Electrophysiol. 2015;8:362–70.

353.

Santangeli P, Frankel DS, Tung R, et al. Early mortality after catheter ablation of ventricular tachycardia in patients with structural heart disease. J Am Coll Cardiol. 2017;69:2105–15.PubMed

354.

Jackson N, McGee M, Ahmed W, et al. Groin haemostasis with a purse string suture for patients following catheter ablation procedures (GITAR study). Heart Lung Circ. 2018. https://doi.org/10.1016/j.hlc.2018.03.011.

355.

Pracon R, Bangalore S, Henzel J, et al. A randomized comparison of modified subcutaneous “Z”-stitch versus manual compression to achieve hemostasis after large caliber femoral venous sheath removal. Catheter Cardiovasc Interv. 2018;91:105–12.PubMed

356.

Ben-Dor I, Craig P, Torguson R, et al. MynxGrip vascular closure device versus manual compression for hemostasis of percutaneous transfemoral venous access closure: results from a prospective multicenter randomized study. Cardiovasc Revasc Med. 2018;19:418–22.PubMed

357.

Robertson L, Andras A, Colgan F, Jackson R. Vascular closure devices for femoral arterial puncture site haemostasis. Cochrane Database Syst Rev. 2016;3:CD009541.PubMed

358.

Jiang J, Zou J, Ma H, et al. Network meta-analysis of randomized trials on the safety of vascular closure devices for femoral arterial puncture site haemostasis. Sci Rep. 2015;5:13761.PubMedPubMedCentral

359.

Dyrda K, Piers SR, van Huls van Taxis CF, Schalij MJ, Zeppenfeld K. Influence of steroid therapy on the incidence of pericarditis and atrial fibrillation after percutaneous epicardial mapping and ablation for ventricular tachycardia. Circ Arrhythm Electrophysiol. 2014;7:671–6.PubMed

360.

Patel AA, Clyne CA, Henyan NN, et al. The use of protamine after radiofrequency catheter ablation: a pilot study. J Interv Card Electrophysiol. 2007;18:155–8.PubMed

361.

Ghannam M, Chugh A, Dillon P, et al. Protamine to expedite vascular hemostasis after catheter ablation of atrial fibrillation: a randomized controlled trial. Heart Rhythm. 2018;15:1642–7.PubMed

362.

Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Circulation. 1997;95:1686–744.PubMed

363.

Frankel DS, Mountantonakis SE, Zado ES, et al. Noninvasive programmed ventricular stimulation early after ventricular tachycardia ablation to predict risk of late recurrence. J Am Coll Cardiol. 2012;59:1529–35.PubMed

364.

Oloriz T, Baratto F, Trevisi N, et al. Defining the outcome of ventricular tachycardia ablation: timing and value of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2018;11:e005602.PubMed

Titel: 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary
verfasst von: Edmond M. Cronin
Frank M. Bogun
Philippe Maury
Petr Peichl
Minglong Chen
Narayanan Namboodiri
Luis Aguinaga
Luiz Roberto Leite
Sana M. Al-Khatib
Elad Anter
Antonio Berruezo
David J. Callans
Mina K. Chung
Phillip Cuculich
Andre d’Avila
Barbara J. Deal
Paolo Della Bella
Thomas Deneke
Timm-Michael Dickfeld
Claudio Hadid
Haris M. Haqqani
G. Neal Kay
Rakesh Latchamsetty
Francis Marchlinski
John M. Miller
Akihiko Nogami
Akash R. Patel
Rajeev Kumar Pathak
Luis C. Saenz Morales
Pasquale Santangeli
John L. Sapp Jr
Andrea Sarkozy
Kyoko Soejima
William G. Stevenson
Usha B. Tedrow
Wendy S. Tzou
Niraj Varma
Katja Zeppenfeld
Publikationsdatum: 20.01.2020
Verlag: Springer US
Erschienen in: Journal of Interventional Cardiac Electrophysiology / Ausgabe 1/2020
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI: https://doi.org/10.1007/s10840-019-00664-2

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Electronic supplementary material

Publisher’s note

1 Introduction

1.1 Document Scope and Rationale

1.2 Methods

2 Background

3 Clinical Evaluation

3.1 Clinical Presentation

3.2 Diagnostic Evaluation

3.2.1 Resting 12-Lead Electrocardiogram

3.2.2 Assessment of Structural Heart Disease and Myocardial Ischemia

3.2.3 Risk Stratification in the Setting of Frequent Premature Ventricular Complexes

3.2.4 Longitudinal Follow-up in the Setting of Frequent Premature Ventricular Complexes

4 Indications for Catheter Ablation

4.1 Idiopathic Outflow Tract Ventricular Arrhythmia

4.2 Idiopathic Nonoutflow Tract Ventricular Arrhythmia

4.3 Premature Ventricular Complexes With or Without Left Ventricular Dysfunction

4.4 Ventricular Arrhythmia in Ischemic Heart Disease

4.5 Nonischemic Cardiomyopathy

4.6 Ventricular Arrhythmia Involving the His-Purkinje System, Bundle Branch Reentrant Ventricular Tachycardia, and Fascicular Ventricular Tachycardia

4.7 Congenital Heart Disease

4.8 Inherited Arrhythmia Syndromes

4.9 Ventricular Arrhythmia in Hypertrophic Cardiomyopathy

5 Procedural Planning

6 Intraprocedural Patient Care

6.1 Anesthesia

6.2 Vascular Access

6.3 Epicardial Access

6.4 Intraprocedural Hemodynamic Support

6.5 Intraprocedural Anticoagulation

7 Electrophysiological Testing

8 Mapping and Imaging Techniques

8.1 Overview

8.2 Substrate Mapping in Sinus Rhythm

8.3 Intraprocedural Imaging During Catheter Ablation of Ventricular Arrhythmias

8.4 Electroanatomical Mapping Systems and Robotic Navigation

9 Mapping and Ablation

9.1 Ablation Power Sources and Techniques

9.2 Idiopathic Outflow Tract Ventricular Arrhythmia

9.3 Idiopathic Nonoutflow Tract Ventricular Arrhythmia

9.4 Bundle Branch Reentrant Ventricular Tachycardia and Fascicular Ventricular Tachycardia

9.5 Postinfarction Ventricular Tachycardia

9.6 Dilated Cardiomyopathy

9.7 Ventricular Tachycardia Ablation in Hypertrophic Cardiomyopathy

9.8 Brugada Syndrome

9.9 Polymorphic Ventricular Tachycardia/Ventricular Fibrillation Triggers

9.10 Arrhythmogenic Right Ventricular Cardiomyopathy

9.11 Mapping and Ablation in Congenital Heart Disease

9.12 Sarcoidosis

9.13 Chagas Disease

9.14 Miscellaneous Diseases and Clinical Scenarios With Ventricular Tachycardia

9.15 Surgical Therapy

9.16 Sympathetic Modulation

9.17 Endpoints of Catheter Ablation of Ventricular Tachycardia

10 Postprocedural Care

10.1 Postprocedural Care: Access, Anticoagulation, Disposition

10.1.1 Postprocedural Care: Access

10.1.2 Postprocedural Care: Anticoagulation

10.2 Incidence and Management of Complications

10.3 Hemodynamic Deterioration and Proarrhythmia

10.4 Follow-up of Patients Post Catheter Ablation of Ventricular Tachycardia

11 Training and Institutional Requirements and Competencies

11.1 Training Requirements and Competencies for Catheter Ablation of Ventricular Arrhythmias

11.2 Institutional Requirements for Catheter Ablation of Ventricular Tachycardia

12 Future Directions

Publisher’s note

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

Appendix

Electronic supplementary material

Weitere Artikel der Ausgabe 1/2020

Exercise-related T-wave oversensing: an underestimated cause of reduced exercise capacity in a pacemaker-dependent patient—a case report and review of the literature

Is paroxysmal supraventricular tachycardia truly benign? Insightful association between PSVT and stroke from a National Inpatient Database Study

Comparing rates of atrioesophageal fistula with contact force-sensing and non-contact force-sensing catheters: analysis of post-market safety surveillance data

Estimation of the accessory pathway location of the manifest Wolf-Parkinson-White syndrome using synthesized right-sided chest leads

Transseptal puncture performed with the new needle-free ‘SafeSept’ guidewire: a multicentre experience

2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias